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Abstract   V 
Abstract 
The c-Myc oncoprotein regulates different aspects of cell behavior by 
modulating gene expression. It was demonstrated that c-Myc stimulates 
cell proliferation, inhibits differentiation, and induces apoptosis. At the 
molecular level, c-Myc acts as a transcription factor by activating or 
repressing target genes. It is suggested that c-Myc exerts many 
functions by binding to other proteins, and several c-Myc-interaction 
partners play roles in the c-Myc-dependent regulation of gene 
expression and cell behavior. Thus, the characterization of novel c-Myc-
binding proteins could give an insight into known as well as novel roles 
of c-Myc. 
To unterstand the function of c-Myc, a screen for novel interaction 
partners was performed by affinity column purifications, and PARP-10 
was found to interact with c-Myc. PARP-10 is a member of the protein 
family of poly(ADP-ribose) polymerases (PARPs) that are protein-
modifying and nucleotide-polymerizing enzymes able to catalyze the 
transfer of multiple ADP-ribose units from NAD+ to substrate proteins. 
Poly(ADP-ribosyl)ation has been reported to regulate many cellular 
processes such as DNA repair, genomic stability, cell cycle progression, 
cell death, and gene transcription.  
The aims of this study were to characterize PARP-10 biochemically and 
biologically, and to analyze the biochemical and functional interaction 
between c-Myc and PARP-10. This study shows that the novel PARP 
family member, PARP-10, is localized to the cytoplasm and the nucleus, 
PARP-10 contains a functional NES that mediates nuclear export which 
is CRM1-dependent. PARP-10 poly(ADP-ribosyl)ates itself and core 
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histones, suggesting that it could play a potential role in the remodeling 
of chromatin. PARP-10 also reduces the proliferation rate of a PARP-10-
inducible cell line, but shows no growth inhibitory effect on colony 
formation. The interaction of PARP-10 with the proto-oncoprotein c-Myc 
was shown in vivo and in vitro, furthermore the interaction occurs in the 
nucleus. c-Myc interacts with the C-terminus of PARP-10. PARP-10 can 
repress the c-Myc-dependent transactivation and inhibit c-Myc/Ha-Ras- 
and E1A/Ha-Ras-dependent transformation indicating that PARP-10 
might repress c-Myc function in target gene regulation and oncogenesis.  
In summary, this study suggests that PARP-10 is a novel PARP enzyme 
that interacts with the proto-oncoprotein c-Myc. PARP-10 inhibits the c-
Myc-dependent transactivation and transformation of rat embryo 
fibroblasts.  
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1 Introduction 
1.1 Proto-oncoprotein c-Myc 
1.1.1 Proto-oncogene c-myc 
myc was originally identified as an oncogene (v-myc) transduced by a number of 
avian retroviruses capable of potently inducing neoplastic disease 
(Myelocytomatosis). Subsequently c-myc, the cellular homologue was identified and 
shown to be a member of the larger family of proto-oncogenes consisting of N-myc, 
L-myc, B-myc and other myc-family genes (Henriksson and Luscher, 1996). The N-
myc and L-myc genes were discovered as amplified or highly expressed genes in the 
childhood tumor neuroblastoma (Kohl et al., 1983; Schwab et al., 1983) and in small 
lung cancer (Nau et al., 1985). c-myc encodes essential genes, because embryos of 
mice carrying a deletion for the c-myc gene die before birth at day E10.5 (Davis et 
al., 1993). c-myc is an inducible gene; since mitogenic stimulation of quiescent 
subconfluent cells induces a rapid increase in both c-myc mRNA and protein levels 
for 1–3 hours (Rabbitts et al., 1985; Kelly and Siebenlist, 1986; Spencer and 
Groudine, 1991). Thereafter, its expression declines to basal level, where it remains 
throughout the cell cycle in continuously proliferating cells. 
 
1.1.2 Expression, function and structure of c-Myc 
c-Myc is evolutionary conserved and has been identified in all vertebrates including 
zebrafish (Schreiber-Agus et al., 1993; Langenau et al., 2003), Drosophila (Gallant et 
al., 1996; Johnston et al., 1999; Orian et al., 2003), and sea star Asterias vulgaris 
(Walker et al., 1992). c-Myc is broadly expressed during embryogenesis and in tissue 
compartments of the adult that possesses a high proliferative capacity. The 
expression of c-Myc strongly correlates with proliferation and in cell cultures. c-Myc is 
rapidly induced in response to a variety of mitogenic stimuli (Grandori et al., 2000). 
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c-Myc is a multifaceted protein that controls regulation of the cell cycle and cell 
growth, activates genomic instability, and stimulates angiogenesis, cell 
transformation and apoptosis. c-Myc both activates and represses transcription of a 
number of target genes (Henriksson and Luscher, 1996). Deregulated expression of 
Myc family proteins (c-, N-, and L-Myc) has been demonstrated in many types of 
cancer. c-Myc expression has since been shown to be altered in a wide variety of 
human tumors including breast, colon, cervical carcinomas, small cell lung 
carcinomas, osteosarcomas, glioblastomas, and myeloid leukemias (Dang et al., 
1999; Nesbit et al., 1999; Grandori et al., 2000).  
The structure of the c-Myc protein is shown in Figure 1-1 (Henriksson and Luscher, 
1996). The c-Myc protein consists of three domains: N-terminal, central, and C-
terminal. The N-terminal domain of c-Myc is involved in activation of transcription 
since it contain a transactivation domain (TAD) and it includes the highly conserved 
Myc box regions (MB1 and MB2) that are unique for the members of the Myc family. 
MB2 is essential for all known Myc biological activities and is the site of interaction 
for a number of cellular proteins. The C-terminal part of c-Myc contains the basic 
helix-loop-helix and leucine zipper (bHLH-LZ) motifs that are necessary for the 
interaction with Max (Myc-associated factor x) (Blackwood and Eisenman, 1991; 
Blackwood et al., 1992) and other proteins (Luscher and Larsson, 1999). The c-Myc 
protein contains two central nuclear localization sequences (NLS). The second NLS 
falls within the basic region (b) implicated in specific DNA sequence recognition and 
binding. The TAD and the bHLH-LZ domains are important for c-Myc-dependent 
transformation, apoptosis and transactivation (Oster et al., 2002). 
 
Figure 1-1. Structure of c-Myc and the obligatoric interaction partner Max. I: Myc box I; II: Myc 
box II; TAD: Transactivation domain; A: acidic domain; NLS: nucleus localization sequence; b: basic 
region; HLH: Helix-Loop-Helix; Zip: leucine zipper; P: phosphorylation site (from Luscher, 2001). 
Introduction  3 
 
1.1.3 The Myc/Max/Mad network 
c-Myc is a bHLH-LZ transcription factor that binds as a heterodimer with Max 
(another bHLH-LZ protein) to a CACGTG sequence (E-box) (Blackwood and 
Eisenman, 1991; Prendergast et al., 1991; Luscher and Larsson, 1999). These 
heterodimers can regulate gene transcription (Luscher and Larsson, 1999). The 
identification of the bHLH-LZ protein Max brought about a search for additional 
bHLH-LZ proteins that could dimerise with Max and bind to E-boxes. The Mad family 
was discovered as Max-binding partners (Ayer et al., 1993; Zervos et al., 1993; 
Hurlin et al., 1995). Together with c-Myc these proteins define the Myc/Max/Mad 
network, where Max is placed in the center (Luscher, 2001) and can promote 
different cellular responses dependent on whether it is bound to Myc or Mad 
proteins. The C-terminal part of c-Myc contains the bHLH-LZ motif that is necessary 
for interaction with Max, the bHLH-LZ motif of Max is necessary for interaction with 
other proteins, including Mad1, Mxi1, Mad3, Mad4, Mga and Mnt. These alternative 
heterodimers can compete for DNA binding with the Myc/Max complex and repress 
transcription through deacetylation of histones, thus antagonizing the transcriptional 
and transforming activities of c-Myc (Henriksson and Luscher, 1996; Grandori et al., 
2000). The Mad proteins expression is preferentially in differentiating cells whereas 
c-Myc is expressed in proliferating cells. It has also been reported that 
overexpression of Mad proteins inhibits c-Myc-activated reporter genes, interferes 
with transformation of rat embryo fibroblasts and prevents apoptosis (Henriksson and 
Luscher, 1996; Gehring et al., 2000; Grandori et al., 2000). These findings place the 
involved proteins in a network where Max/Myc and Max/Mad have antagonistic 
functions.  
Furthermore, c-Myc can also interact with additional proteins and this can occur both 
in the N- and C-terminal regions of c-Myc. Examples of proteins that interact with the 
N-terminus of c-Myc are p107 (Beijersbergen et al., 1994; Gu et al., 1994), Bin1 
(Sakamuro et al., 1996), TRRAP (McMahon et al., 1998) and TBP (Hateboer et al., 
1993) while proteins that interact with the C-terminus include YY1 (Shrivastava et al., 
1993), CBP/P300 (Vervoorts et al., 2003), AP2 (Gaubatz et al., 1995), TFII-I (Roy et 
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al., 1993), Miz1 (Peukert et al., 1997), Nmi (Bao and Zervos, 1996) and Brca1 (Wang 
et al., 1998b). Miz1, YY1, AP2 and TFII-I are transcriptional activators and interaction 
with c-Myc leads to their inhibition. Bin1, Brca1 and the pRb related protein p107 
seem to be negative regulators of c-Myc and inhibit c-Myc-dependent transactivation 
and Ras cotransformation (Sakamuro et al., 1996; Wang et al., 1998b; Elliott et al., 
1999). TRRAP interacts with the conserved domain MB2 of c-Myc (McMahon et al., 
1998; Park et al., 2001) and results in enhanced transcriptional activation (Liu et al., 
2003). CBP/p300 bind to the C-terminal region of c-Myc (Vervoorts et al., 2003) and 
the interaction leads to transcriptional activation (Vervoorts et al., 2003). 
 
1.1.4 Target genes of c-Myc 
A number of c-Myc-target genes have been identified during the last several years. 
These target genes are involved in processes that control cell growth, proliferation, 
differentiation, transcription, the cell cycle and apoptosis and can be divided into 
groups based on their function. Some identified target genes of c-Myc include the 
following: 1. Genes involved in apoptosis: gadd45, p19Ink4d and p53 (Reisman et al., 
1993; Zindy et al., 1998). 2. Genes involved in cell cycle progression: CDC 25a 
(Galaktionov et al., 1996), cyclin D2 (Bouchard et al., 1999), p21Cip1(Claassen and 
Hann, 1999), p15Ink4b(Warner et al., 1999), cul1 (O'Hagan et al., 2000a) and CDK 4 
(Menssen and Hermeking, 2002). 3. Genes involved in growth and metabolism: cad 
(Miltenberger et al., 1995), eIF-2α (Rosenwald et al., 1993), eIF4E (Rosenwald et al., 
1993), ornithine decarboxylase (ODC) (Bello-Fernandez et al., 1993), LDH-A (Shim 
et al., 1997), α-prothymosin (Eilers et al., 1991), DHFR (Mai and Jalava, 1994), H-
ferritin, iron regulatory protein 2 (IRP2) (Wu et al., 1999), and thymidine kinase 
(Pusch et al., 1997). 4. Genes involved in immortalization: hTert (Wang et al., 1998a; 
Wu et al., 1999; O'Hagan et al., 2000b). 5. Genes involved in transcription: tip48, c-
myc, pcaf and polr2f (O'Hagan et al., 2000b; Menssen and Hermeking, 2002). 
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1.1.5 Effect of c-Myc on cell cycle progression 
A substantial amount of c-Myc’s target genes are involved in the control of cell 
proliferation. It has been reported that c-Myc is sufficient to overcome the restriction 
point and to induce S phase in the absence of growth factors (Eilers, 1999). Some 
components of the cyclin/CDK (cyclin-dependent kinase) network are direct targets 
of c-Myc, including cyclin D1, cyclin D2 and CDK 4. Once cyclin D1 and cyclin D2 are 
upregulated they can sequester the CKI p27Kip1 which is an inhibitor of cyclin E/CDK 
2 which in turn is essential for overcoming the restriction point. Furthermore the 
expression of cyclin E/CDK 2 is enhanced by activation of the c-Myc target gene 
CDC 25a (Galaktionov et al., 1996) which stimulates cyclin E/CDK 2 activity 
(Blomberg and Hoffmann, 1999; Sexl et al., 1999). The CKI p27Kip1 is further 
controlled by the upregulation of Cul1 (O'Hagan et al., 2000a) which is part of the 
SCF E3 ligase participating in the proteasomal degradation of p27Kip1. In addition 
p27Kip1 can be repressed directly by c-Myc (Yang et al., 2001). c-Myc can activate 
Id2 (Lasorella et al., 2000), which is a negative regulator of pocket proteins, including 
RB, and can stimulate progression through the restriction point. These c-Myc-
dependent regulations result in the stimulation of cyclin D- and cyclin E-dependent 
kinase activities and in the inhibition of pocket proteins. 
 
1.1.6 c-Myc and transformation 
c-Myc by itself does not transform primary rodent cells, but does to in combination 
with Ras and socalled foci are formed (Land et al., 1983). Ras encodes a small 
GTPase that is mutated in many human tumors (Downward, 2003). The activation 
state of Ras is controlled by the cycle of hydrolysis of bound GTP. When bound to 
GTP, Ras is active and can engage downstream target enzymes; when bound to 
GDP Ras is inactive (Campbell et al., 1998). In its activated state, Ras controls 
distinct signaling pathways, including the Raf/MEK-kinase pathway, the RalGDS 
pathway, and the PI3-kinase (phosphoinositide 3-kinase) pathway (Rodriguez-
Viciana et al., 1994; Pacold et al., 2000; Hamad et al., 2002). 20% of all human 
tumors have an activating mutation in one of the ras genes (Bos, 1989) and activated 
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Ras contributes significantly to several aspects of the malignat phenotype (Shields et 
al., 2000). The mechnism of transformation by Ras and c-Myc is not completely 
understood. A number of recent observations show that c-Myc specifically co-
operates with active PI3-kinase in deregulating cell proliferation.  
Recently it was reported that co-operativity between c-Myc and Ras might include in 
FoxO (forkhead box O; forkhead members of the O class) pathway (Bouchard et al., 
2004). FoxO proteins are transcription factors that function under the control of 
insulin/insulin-like signaling. FoxO factors have been associated with a multitude of 
biological processes, including cell-cycle, cell death, DNA repair, metabolism and 
protection from oxidative stress (Medema et al., 2000; Van Der Heide et al., 2004). 
Akt-mediated phosphorylation of FoxO transcription factors is important for the PI3-
kinase pathway. In a non-phosphorylated state, FoxO factors can inhibit induction of 
multiple c-Myc target genes, c-Myc-induced cell proliferation and transformation by c-
Myc and Ras. Abrogation of FoxO function enables c-Myc to activate target genes in 
the absence of PI3-kinase activity and to induce foci formation in primary cells in the 
absence of oncogenic Ras (Bouchard et al., 2004).  
c-Myc can transcriptionally activate oncogenes such as cyclin D1, cyclin D2, CDK 4 
and CDC 25, since they increase the pRb phosphorylation and the cells become 
resistant to growth inhibition signals, which leads to transformation (Vlach et al., 
1996; Perez-Roger et al., 1999). Many c-Myc regulated genes are involved in 
transformation, e.g. TERT (telomerase reverse transcriptase), the catalytic subunit of 
telomerase, can be induced by c-Myc (Cerni, 2000). Telomerase is an enzyme that 
adds telomere repeat sequences to the 3' end of DNA strands. By lengthening this 
strand DNA polymerase is able to complete the synthesis of the "incomplete ends" of 
the opposite strand. It was shown that most (85–90%) cancer cells have regained 
the ability to synthesize high levels of telomerase throughout the cell cycle, and thus 
are able to prevent further shortening of their telomeres. c-Myc up-regulates 
telomerase activity in primary mouse embryonic fibroblasts (MEFs) and myeloid 
cells. c-Myc overexpression in immortal cells (e.g. c-Myc/Ras transformed cells) 
results in discordant regulation of TERT and telomerase activity (Drissi et al., 2001; 
Pelengaris et al., 2002).  
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1.1.7 c-Myc-dependent transactivation and repression 
The c-Myc protein is a transcription factor that positively or negatively regulates 
expression of distinct sets of target genes. Transcriptional activation by c-Myc is 
mediated through dimerization with Max and binding to the DNA consensus 
sequence the E-box T. Transcriptional inhibition is mediated through distinct DNA 
elements, and may be due to functional interference with factors that transactivate 
via these sequences (Henriksson and Luscher, 1996). 
The N-terminus of c-Myc is required for transactivation and is essential for mediating 
its oncogenic effects. The TAD of c-Myc can interact with a number of proteins, few 
of these provide clues to the mechanism of c-Myc induced transcriptional activation. 
During recent years new findings have suggested that c-Myc might associate with 
histone acetyltransferases (HAT) and SWI/SNF complexes. A novel ATM-related 
factor, TRRAP, interacts with the conserved domain MB2 of c-Myc (McMahon et al., 
1998; Park et al., 2001). TRRAP is a large protein that functions in complexes 
containing HAT like GCN5 and Tip60. Furthermore, c-Myc seems to recruit a Tip60 
complex through interaction with TRRAP (Fuchs et al., 2001). Two proteins, Tip48 
and Tip49, bind to c-Myc and it has been shown that the ATPase activity of Tip49 is 
essential for c-Myc oncogenic activity (Wood et al., 2000). Tip48 and Tip49 can 
further interact with BAF53 (Park et al., 2002) which seems to be a component of 
STAGA (Spt3/TAF/GCN5/Acetylase) and Tip60 complexes. Additionally, recruitment 
of both TRRAP and GCN5 activity has been suggested to be mediated by direct 
binding of the c-Myc N-terminus to the human STAGA coactivator complex which 
results in enhanced transcriptional activation (Liu et al., 2003). c-Myc can interact 
with INI1/hSNF5 through its C-terminus. INI1/hSNF5 is a component of the 
multiprotein SWI/SNF complex involved in chromatin remodeling in an ATP-
dependent manner (Cheng et al., 1999; Kingston and Narlikar, 1999). Although the 
recruitment of the SWI/SNF complex is necessary for c-Myc transactivator function in 
reporter gene assays, the role of this complex for the regulation of chromosome 
embedded target genes is not yet clear. It has previously been shown that that c-Myc 
activates transcription of its target gene cad at a post-Pol II recruitment step and that 
Introduction  8 
the c-Myc TAD interacts with a number of cyclin/CDK complexes (Eberhardy and 
Farnham, 2001). It has recently been demonstrated that cyclin T1 and CDK 9 binding 
to c-Myc is sufficient for activation of a synthetic promoter construct, suggesting that 
c-Myc activates transcription by stimulating elongation (Eberhardy and Farnham, 
2001). The coactivators CBP/p300 are HATs that bind to the C-terminal region of c-
Myc (Vervoorts et al., 2003). These HAT enzymes function at least in part by 
acetylating core histones, a mechanism that has been linked to chromatin opening 
and gene activation. In agreement binding of Myc/Max heterodimers to E-box 
elements correlates with altered core histone acetylation at target promoters and 
increased transcription (Vervoorts et al., 2003).  
While the function of c-Myc as a transcriptional activator has been well studied and 
evidence for this has steadily accumulated over recent years, the role of c-Myc in 
transcriptional repression has been less clear. Originally, one of the first biological 
functions described for c-Myc was the ability to inhibit the differentiation process of 
pre-adipocytes to adipocytes in culture by repressing the transcription of the C/EBP-
α gene (Freytag and Geddes, 1992). It was subsequently shown that this repression 
was mediated by the core of the C/EBP-α promoter and it was suggested that c-Myc 
controls transcription directly or indirectly through the core C/EBP-α promoter (Li et 
al., 1994). c-Myc has been shown to repress a number of promoters of cell 
cycle/growth arrest genes including gas1, p15Ink4a, p21Cip1, p27Kip1 and gadds (Gartel 
and Shchors, 2003). The initiator (Inr) element of several of these promoters has 
been suggested to mediate the repressor activity of c-Myc (Li et al., 1994; Mai and 
Jalava, 1994; Philipp et al., 1994; Lee et al., 1996). Recent studies have shown that 
the c-Myc interaction partner Miz-1 binds to and activates transcription from Inr 
elements, arrests cells in G1 phase and inhibits cyclin D-associated kinase activity 
(Peukert et al., 1997; Seoane et al., 2001; Staller et al., 2001; Herold et al., 2002). 
Miz-1 upregulates expression of the cyclin-dependent kinases inhibitor p15INK4b by 
binding to the initiator element of the p15INK4b promoter. c-Myc and Max form a 
complex with Miz-1 at the p15 initiator element and inhibit transcriptional activation 
by Miz-1. 
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1.2 Modification of chromatin 
The control of gene expression is one of the most fundamental processes in biology 
and contains many layers of complexity. Genomic DNA is organised into chromatin in 
which DNA is packaged into nucleosomes which represent the basic repeating units 
of chromatin. Nucleosomes consist of two superhelical turns of DNA wrapped around 
an octamer of core histone proteins formed by four histone partner, one H3-H4 
tetramer and two H2A-H2B dimers. Histones are small basic proteins consisting of a 
globular domain and a more flexible and charged NH2-terminus (the “tail”) that 
protrudes from the nucleosomes (Jenuwein and Allis, 2001). The tail can be modified 
by various enzymatic activities. Arrays of nucleosomes contain the linker histone H1 
that twists and folds the chromatin fibre into increasingly more compact filaments and 
thereby gives rise to a defined higher order structure. The regular nucleosomal 
arrays comprise a 10-nm fiber of chromatin and folds into a 30-nm fiber in the 
presence of H1. In order for transcription to take place (i.e. to allow for binding of 
regulatory factors and PIC formation), the higher ordered and highly condensed 
chromatin structure has to be altered. Higher levels of chromatin compaction involve 
additional proteins, many of which are unknown, in order to achieve the astounding 
degree of condensation required to yield mitotic chromosomes. Tightly packed and 
therefore inaccessible chromatin is referred to as heterochromatin whereas 
chromatin that has a more loose structure and is therefore accessible is referred to 
as euchromatin. Structural transitions in chromatin also depend on the core domains 
of histones, which are responsible for the compaction of DNA and for establishing 
protein-protein interactions. These core domains are flanked by variable N- and C-
terminal regions that can be acetylated, methylated, ubiquitylated, phosphorylated 
and poly(ADP-ribosyl)ated (van Holde, 1988; Wolffe, 1998; Wolffe and Hayes, 
1999). Histone acetylation has been associated with actively transcribed genes 
(Brownell et al., 1996; Ogryzko et al., 1996; Kuo et al., 1998) whereas histone 
deacetylation has been associated with silenced genes (Taunton et al., 1996; Alland 
et al., 1997; Hassig et al., 1997; Nagy et al., 1997; Hassig et al., 1998; Wong et al., 
1998). The tails of core histones are acetylated by HATs (histone acetyltransferase) 
on specific lysine residues. Acetylation of histone tails is suggested to lead to a more 
"open" chromatin structure and this increased accessibility to general transcription 
factors, the Pol II holoenzyme and to additional gene regulatory proteins. HDACs 
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(histone deacetyltransferase) in general remove acetyl groups from histone tails. 
This regains the positive charge of lysine and reverse the effects of histone 
acetylation. At the chromatin level, localised histone deacetylation can stabilise 
nucleosomal structure and internucleosomal histone-histone interactions to inhibit 
the DNA accessibility of transcriptional activators and the general transcription 
machinery.  
It has been recognised that chromatin structure plays an important regulatory role 
since multiple signaling pathways converge at histone tails. Specific modification of 
histones seems to correlate with specific transcriptional states. The combination of 
different modification on the same histone tail has been proposed to function as a 
“histone code” (Strahl and Allis, 2000; Turner, 2002; Iizuka and Smith, 2003; Lachner 
et al., 2003) which extends the information content of the genome past the genetic 
code. The combination of different modification on the same histone tail has been 
proposed to function as a “histone code”, and this can be read by other proteins to 
bring about distinct downstream events, e.g. activation or repression transcribed 
genes.  
Different sets of combinatorial modifications have been shown for example with core 
histone H3. H3 can be modified at K4, K9 and K14 by acetylation, at S10 by 
phosphorylation and at R17 by methylation. Around K9/S10/K14 there appears to be 
specific patterns for activity and inactivity. The inactive state of H3 is characterised 
by deacetylation at K14 which is preceded methylation at K9 (Noma et al., 2001). On 
the other hand, acetylation at K14 is preceded by and dependent upon 
phosphorylation of S10 (Cheung et al., 2000; Lo et al., 2000; Rea et al., 2000). 
The other way of altering chromatin structure is chromatin remodeling: the use of 
protein complexes that utilise the energy derived from hydrolysis of ATP to perturb or 
reorganise chromatin structure by destabilisation and displacement of histone-DNA 
contacts (Wolffe and Hayes, 1999).  
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1.3 Poly(ADP-ribosyl)ation 
Almost 40 years ago, Chambon and colleagues discovered that the addition of 
nicotinamide mononucleotide (NMN) to rat liver nuclear extracts stimulated the 
synthesis of a polyadenylic acid (Chambon et al., 1963), later identified as poly(ADP-
ribose) (PAR) (Ame, 2001). With this discovery began research on PAR and the 
enzymes that regulate its metabolism, in particular poly(ADP-ribose) polymerases 
(PARP). Poly(ADP-ribosyl)ation is a post-translational modification, which can cleave 
NAD+ to nicotinamide and ADP-ribose, forming negatively charged linear or long-
branched (ADP-ribose) polymers on glutamic residues of PARP enzyme itself and 
acceptor proteins (Szabo and Dawson, 1998; D'Amours et al., 1999). PARP activity 
has been reported in all higher eukaryotes studied so far, and in most lower 
eukaryotes (Brightwell et al., 1975; Laroche et al., 1980; Werner et al., 1984; 
Scovassi et al., 1986; Burtscher et al., 1987; Kofler et al., 1993; Uchida et al., 1993; 
Chen et al., 1994; Lepiniec et al., 1995; Babiychuk et al., 1998), with the notable 
exception of yeast (Ruggieri et al., 1990; Park et al., 1991). In addition, poly(ADP-
ribosyl)ating activity appears to be present in the archaeal domain, since a PARP-like 
enzyme has been identified in Sulfolobus solfataricus (Faraone-Mennella et al., 
1998).  
 
1.3.1 PARP-1  
The best studied poly(ADP-ribosyl)ating enzyme, PARP-1, also known as poly(ADP-
ribose) synthetase and poly(ADP-ribose) transferase, is a DNA nick sensor and uses 
NAD+ to form polymers of ADP-ribose which are further bound to nuclear protein 
acceptors (de Murcia and Menissier de Murcia, 1994; D'Amours et al., 1999). Most 
studies have been done with PARP-1 and before other PARPs were identified, 
PARP-1 was referred to as PARP. A schematical view of PARP metabolism is shown 
in Figure 1-2. Polymers of poly(ADP-ribose) vary in length from a few to as many as 
200 ADP-ribose units following DNA damage. PARP-1 binds to single- and double-
strand DNA breaks and its catalytic activity is stimulated by DNA breaks in vitro and 
in vivo (Durkacz et al., 1980; Purnell et al., 1980). Addition of the negative charge 
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can drastically affect the activity of acceptor proteins and poly(ADP-ribosyl)ation has 
been reported to regulate many cellular processes such as DNA repair, genomic 
stability, cell cycle progression, cell death (Eliasson et al., 1997; Endres et al., 1997) 
and gene transcription (Kraus and Lis, 2003; Tulin and Spradling, 2003). 
 
Figure 1-2. Metabolism of poly(ADP-ribose). Poly(ADP-ribose) polymerase-1 (PARP-1) hydrolyzes 
NAD+ to polymerize ADP-ribose units on substrate proteins, with the concomitant release of 
nicotinamide. PARP-1 catalyzes the three steps of poly(ADP-ribose) anabolism (red part of the cycle): 
mono(ADP-ribosyl)ation of the acceptor protein substrate; elongation; and branching of the poly(ADP-
ribose) chain. Branching occurs on average every 20 to 50 ADP-ribose units. The negatively charged 
poly(ADP-ribose) has a short half-life owing to poly(ADP-ribose) glycohydrolase (PARG) (green side of 
the cycle) that is activated by an increase in the cellular concentration of poly(ADP-ribose). PARG has 
exoglycosidic and endoglycolytic activities that cleave glycosidic bonds between ADP-ribose subunits 
located at the ends and within the poly(ADP-ribose) chains, respectively (cleavage sites shown by dark 
green arrows) (from Rouleau et al., 2004). 
PARP-1 is a 116-kDa protein consisting of three main domains (Figure 1-3): the N-
terminal DNA binding domain containing two zinc fingers, the automodification 
domain, and the C-terminal catalytic domain. The DNA-binding domain, 
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characterized by the presence of two zinc fingers and a nuclear localization signal, 
plays a crucial role in the recognition of DNA strand breaks and concomitant 
activation of PARP-1 (Benjamin and Gill, 1980; Ikejima et al., 1990; D'Amours et al., 
1999). The automodification domain comprises a BRCT module that mediates 
several protein-PARP-1 interactions. This domain is found in numerous proteins 
involved in the DNA damage response and cell cycle control (D'Amours et al., 1999). 
PARP-1 automodification thus regulates both protein-PARP-1 and DNA-PARP-1 
interactions (Mazen et al., 1989; de Murcia and Menissier de Murcia, 1994; de 
Murcia et al., 1994; Schreiber et al., 1995; Smith, 2001). The primary structure of the 
enzyme is highly conserved in eukaryotes (human and mouse enzyme have 92% 
homology at the level of amino acid sequence) with the catalytic domain showing the 
highest degree of homology between different species; the catalytic domain contains 
the PARP signature sequence, a 50-amino acid block showing 100% homology 
between vertebrates. The most dramatic elevations in PARP-1 activity are mediated 
by single-strand breaks, although significant stimulation also occurs following 
recognition of double-strand breaks (Weinfeld et al., 1997). Wenn DNA damage 
occures, the poly(ADP-ribose) synthesis rise in 10 to 500-fold and this translates into 
intracellular signals that trigger DNA repair and/or cell death pathways. In conditions 
of low-to-moderate levels of DNA damage, the activation of PARP-1 causes rapid 
self-poly(ADP-ribosyl)ation and covalent modification of histones and other 
chromatin proteins (Okayama and Hayaishi, 1978; Levy-Wilson, 1981; Mennella et 
al., 1982; Poirier et al., 1982b; Tanuma et al., 1983; Adamietz and Rudolph, 1984; 
Adolph and Song, 1985b; Adolph and Song, 1985a; Tanuma et al., 1985; Krupitza 
and Cerutti, 1989a; Krupitza and Cerutti, 1989b; Scovassi et al., 1993; Ullrich and 
Grune, 2001). Modified proteins lose their affinity for DNA owing to the high negative 
charge of poly(ADP-ribose). These events are believed to “prime” the damaged site 
for the subsequent repair of DNA single-strand breaks by base excision repair (BER) 
(Kimchi et al.). Although the exact functions of PARP-1 and poly(ADP-ribose) in BER 
remain to be fully deciphered, several lines of evidence support roles in local 
chromatin remodeling, protection of DNA breaks, and recruitment and modulation of 
the activity of repair factors, including XRCC1, DNA ligase III, DNA polymerase ß 
and FEN-1, which are part of the BER complex (Dantzer et al., 2000; Lavrik et al., 
2001; Prasad et al., 2001; El-Khamisy et al., 2003; Leppard et al., 2003; Okano et 
al., 2003). 
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Experiments in Drosophila and mammalians show interactions between PARP-1 and 
promoter/enhancer elements and transcription factors (including NF-κB, B-MYB, Oct-
1, AP-2, RXRa nuclear receptors, HTLV Tax-1 protein, PC1, E47, YY1, p53, DF-1, 
TBP and TEF-1) (Simbulan-Rosenthal et al., 1996; Wesierska-Gadek et al., 1996; 
Kumari et al., 1998; Malanga et al., 1998b; Ariumi et al., 1999; Kannan et al., 1999; 
Oliver et al., 1999; Simbulan-Rosenthal et al., 1999; Cervellera and Sala, 2000; 
Mendoza-Alvarez and Alvarez-Gonzalez, 2001; Oei and Shi, 2001a; Oei and Shi, 
2001b; Simbulan-Rosenthal et al., 2001; Tong et al., 2001; Wesierska-Gadek and 
Schmid, 2001; Tulin et al., 2002; Kraus and Lis, 2003; Tulin and Spradling, 2003). 
PARP-1 can act as a positive coactivator of E2F-1-mediated transcription during re-
entry of quiescent cells into S phase. In contrast to other PARP-1 interactions, 
PARP-1 does not poly(ADP-ribosyl)ate E2F-1 but binds to it independently of its DNA 
and catalytic domains (Simbulan-Rosenthal et al., 2003). In neuronal cells in 
response to massive DNA damage, PARP-1 activation signals apoptosis-inducing 
factor (AIF) release from the mitochondria which translocates to the nucleus resulting 
in a caspase-independent pathway of apoptosis (Dawson and Dawson, 1995; 
Dawson and Dawson, 2004). However, overactivation of PARP-1 leads to depletion 
of NAD+ and hence also to depletion of overall ATP, resulting in energy deprivation, 
often followed by necrosis. Modulation of NAD+ levels by PARP-1 has a linkage to 
the Sir2 histone deacetylase, which depends on high NAD+ and low nicotinamide 
levels for deacetylation (Zhang, 2003; Zhao et al., 2004). In addition, poly(ADP-
ribosyl)ation can antagonize DNA methylation and maintain heterochromatin in a 
relatively relaxed state (Zardo et al., 1997; Zardo and Caiafa, 1998; de Capoa et al., 
1999). Inhibition of poly(ADP-ribosyl)ation results in hypermethylation and increased 
compaction of heterochromatin and was suggested recently as co-regulator of DNA 
methylation leading to epigenetic reprogramming of cancer cells (Althaus, 2005; 
Tentori et al., 2005). 
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Figure 1-3. PARP superfamily. Details are described in the text (from Ame et al., 2004). 
 
1.3.2 PARG  
Poly(ADP-ribosyl)ation is a dynamic process, the half-life of the polymer is short (<1 
min.) in vivo (Whitacre et al., 1995). The poly (ADP-ribose) glycohydrolase (PARG), 
the enzyme that cleaves the ribose-ribose bond was discovered in 1971 by Masanao 
Miwa and Takashi Sugimura (Miwa and Sugimura, 1971) and by Ueda et al. (Ueda et 
al., 1972). These authors observed that homogenates of various mammalian cells 
generate AMP and ADPr from polymers of ADPr. This observation could not be 
explained by a phosphodiesterase activity, since phosphodiesterase hydrolyses PAR 
into phosphoribosyl-AMP (Miwa and Sugimura, 1971; Ueda et al., 1972). The 
poly(ADP-ribose)-specific endo- and exoglycosidic activities of PARG make poly(ADP-
ribosyl)ation transient and reversible (Oka et al., 1984; Desnoyers et al., 1995). PARG 
activity generates both free ADP-ribose units and poly(ADP-ribose) polymers. A free 
ADP-ribose terminus can be further cleaved by PARG or re-polymerized by a PARP. 
The release of the ADP-ribose unit most proximal to the protein is catalyzed by PARG 
and/or by ADP-ribosyl protein lyase. PARG activity in part depends on the size of the 
poly(ADP-ribose) chain, being most active against long chains. To date, only a single 
PARG gene has been detected in mammals. PARG activity has been detected in both 
the cytoplasm and the nucleus and can shuttle between the cytoplasm and the 
nucleus (Winstall et al., 1999; Bonicalzi et al., 2003; Ohashi et al., 2003). 
The endoglycosylase activity of PARG is physiologically important, because it is 
responsible for the generation of protein-free ADPr polymers that can interact with 
histones and other nuclear proteins (Panzeter et al., 1992; Thibeault et al., 1992; 
Panzeter and Althaus, 1994). 
Snake venom phosphodiesterase can cleave poly(ADP-ribose) as well. It cleaves the 
adjoining phosphates of ADP-ribose units, but endogenous mammalian equivalents 
have been little characterized (Futai et al., 1968; Miwa and Sugimura, 1982; Aravind, 
2001). The recent description of the macro domain structure found in histone 
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macroH2A and in several PARPs (Aravind, 2001) suggests that this domain has 
phosphoesterase activity directed towards poly(ADP-ribose) (Allen et al., 2003; 
Ladurner, 2003). Interestingly, cleavage of poly(ADP-ribose) by a nuclear 
phosphodiesterase is predicted to leave a terminal phosphate group that could not be 
further cleaved by PARG or extended by a PARP. Such an event might allow the cell 
to “tag” specific proteins irreversibly in order to secure their function, as has been 
proposed for silencing of the X-chromosome by histone macroH2A (Allen et al., 2003).  
 
1.3.3 PARP and chromatin remodeling 
The involvement of PARP in chromatin remodeling is interesting, because many 
PARP-1 substrates are involved in establishing chromatin architecture (e.g. histones 
and their variants, high-mobility group (HMG) proteins and topoisomerases). Histones 
H1, H2A and H2B are the major poly(ADP-ribosyl)ated chromatin proteins (Huletsky et 
al., 1985). An in vitro poly(ADP-ribose) turnover assay suggested that at low, 
physiological levels of activation of PARP-1 poly(ADP-ribosyl)ation of nucleosome 
cores is favoured and of a local area of structural plasticity is established, whereas 
overt stimulation, such as when the genome accumulates DNA strand breaks, leads to 
hyper-modification of linker histone H1 and concomitant dramatic relaxation of the 
chromatin architecture.  
Poly(ADP-ribose) polymers can non-covalently associate with nuclear proteins as well. 
Histones, heterogeneous nuclear ribonucleoproteins, the tumor suppressor p53, 
p21Cip1/Waf1 and lamins all specifically bind both to free poly(ADP-ribose) and 
poly(ADP-ribose) covalently attached to automodified PARP-1. This is mediated by a 
novel binding motif consisting of alternating hydrophobic and basic residues, which 
confers affinity for poly(ADP-ribose) (Pleschke et al., 2000; Gagne et al., 2003). The 
poly(ADP-ribose)-binding domains for non-covalent interactions have been identified 
on histones H1, H2A, H2B, H3 and H4 (Panzeter et al., 1993; Malanga et al., 1998a). 
The non-covalent interaction with histone H1 occured by the C-terminal region which 
is involved in generating higher-oder chromatin structure (Panzeter et al., 1993; 
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Plaschke et al., 2000). In each of the core histones, the binding site lies at the junction 
of the N-teminal tail and helix I of the histone fold. Several charged residues in this 
sequence lie on the exterior of the fully assembled core histone octamer, which 
favours interaction with DNA or poly(ADP-ribose), and the remaining residues involved 
in histone dimer formation (Arents and Moudrianakis, 1995). This indicates that the 
binding of poly(ADP-ribose) by a single core histone could be sufficient to alter internal 
nucleosomal organization. 
A “histone shuttle” mechanism (Realini and Althaus, 1992) for chromatin 
relaxation/recondensation could be explained with the affinity of histones for 
poly(ADP-ribose), especially on automodified PARP-1: PARP-1 activated by DNA 
strand breaks at the site of damage, and the synthesized poly(ADP-ribose) could 
locally dissociate histones from chromatin. Poly(ADP-ribose) would then serve as a 
scaffold onto which histones could be sequestered in order to facilitate repair. 
Subsequent cleavage of poly(ADP-ribose) by PARG would then allow histone-DNA 
complexes to reform. In addition, H1 remains associated with chromatin relaxed by 
poly(ADP-ribosyl)ation in vitro (Poirier et al., 1982a; Aubin et al., 1983). Although 
these non-covalent interactions have yet to be demonstrated to occur in vivo, the 
identification of the poly(ADP-ribose)-binding motif in proteins involved in chromatin 
architecture (e.g. histones) and in DNA repair (e.g. DNA ligase III and XRCC1) 
supports the concept of poly(ADP-ribose) serving as a scaffold for the recruitment and 
assembly of DNA repair machinery. Poly(ADP-ribosyl)ation confers negative charge to 
histones, leading to electrostatic repulsion between DNA and histones. This process 
has been implicated in chromatin remodeling, DNA repair, and transcriptional 
regulation (Kraus and Lis, 2003; Tulin and Spradling, 2003). 
In addition, it is interesting to note that multiple parallels can be drawn between PARP-
1 and other histone- and chromatin-modifying enzymes, e.g. histone 
acetyltransferases (HATs) and ATP-dependent chromatin remodelers (Vaquero et al., 
2003). PARP-1 can affect other histone-modifying coactivators (Kraus and Wong, 
2002). Furthermore, PARP-1 is likely to operate in a synergistic manner in 
combination with other chromatin-related factors: nucleosomes can be simultaneously 
poly(ADP-ribosyl)ated and acetylated (Malik and Smulson, 1984). 
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1.3.4 Other PARP members 
Beside PARP-1, 17 other proteins containing PARP domains have recently emerged 
from genome sequencing and various molecular and genetic approaches (Ame et al., 
2004). They can again be divided in three subgroups (Figure 1-3).  
PARP-2, PARP-3 and PARP-4 (VPARP), together with PARP-1 belong to the PARP-1 
subgroup. PARP-2 is a component of the BER complex and it too contains a short N-
terminal DNA-binding domain, a C-terminal automodification/catalytic domain and a 
caspase 3 cleavage site at the junction between these two domains. PARP-2 interacts 
with PARP-1 and shares common partners involved in the Single Strand Break Repair 
(SSBR) and BER pathways (Dantzer et al., 2004). PARP-1 and PARP-2 interact with 
proteins involved in the kinetochore structure and in the mitotic spindle checkpoint. 
PARP-2 may have a function with telomere integrity control since it interacts with the 
telomeric protein TRF. PARP-3 localizes to both the nucleus and the cytoplasm, and 
in addition is associated with the daughter centriole throughout the cell cycle (Augustin 
et al., 2003). PARP-3 interacts with PARP-1 in the centrosome and may have function 
in DNA damage surveillance and the mitotic fidelity checkpoint (Kanai et al., 2003). 
PARP-4 associates with vault particles (Kickhoefer et al., 1999), may functionally be 
associated with multidrug resistance in some cell lines and was suggested to be 
important in cellular transport; PARP-4 localizes to the nuclear pores and associates 
with the mitotic spindle during mitosis. PARP-6, PARP-8 and PARP-16 belong to the 
PARP-1 subgroup as well (Ame et al., 2004). Till now, their functions are not clear yet. 
The Tankyrase group contains PARP-5a (Tankyrase 1: TRF1-interacting, ankyrin-
related ADP-ribose polymerase), PARP-5b (Tankyrase-2) and PARP-5c. PARP-5a 
and PARP-5b show multiple subcellular localizations: telomeres, nuclear pores, Golgi 
vesicles and pericentriolar material (PCM) during mitosis. PARP-5a was identified as a 
binding partner of human telomeric protein TRF1 in a two-hybrid screening (Smith et 
al., 1998). Overexpression of PARP-5a results in ADP-ribosylate of TRF1, leads to 
TRF1 release from telomeres and telomere elongated. PARP-5a expession is 
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regulated by ubiquitination and degradation by the proteasome. Downregulation of 
PARP-5a by siRNA blocks the cells in early anaphase because sister telomeres are 
unable to segregate. This suggests that the replicated telomeres are held together by 
specific cohesion complexes that are resolved by PARP-5a. PARP-5a and PARP-5b 
interact with the same proteins including TRF1, IRAP, Glut4, Grb14, TAB182 and 
NuMa (Kaminker et al., 2001; Lyons et al., 2001; Cook et al., 2002; Sbodio et al., 
2002). They are suggested to mediate overlapping functions in telomere homeostasis 
and vesicle trafficking (glucose transport and insulin signaling).  
The rest of PARP members belong to the third subgroup. PARP-9 (Bal), PARP-14 and 
PARP-15 contain a duplicated A1pp domain (macro domain) and therefore are 
classified as macro PARPs. This domain is found in a number of otherwise unrelated 
proteins, including at the C-terminus of the macro-H2A histone protein H2AY_RAT 
and in the non-structural proteins of several types of ssRNA viruses such as NSP3 
from alphaviruses. This domain is also found on its own in a family of proteins from 
bacteria, archaebacteria and eukaryotes, suggesting that it is involved in an important 
and ubiquitous cellular process (Allen et al., 2003; Ame et al., 2004). PARP-9 is a 
nuclear protein encoded by the BAL gene, which is expressed at a significantly higher 
level in fatal high-risk DLBCLs (diffuse large B-cell lymphomas) and may be implicated 
in B-cell migration (Aguiar et al., 2000). PARP-7 (tiPARP), PARP-10, PARP-11, 
PARP-12, PARP-13 and PARP-14 belong to WWE PARPs. PARP-7, PARP-11 to 
PARP-14 contain WWE domain that exists in classes of proteins associated with 
ubiquitination (Aravind, 2001); PARP-10 contain a Ubiquitin Interaction Motif (UIM) 
that link to ubiquitination as well. WWE PARPs are suggest to be associated with 
regulation of protein transport. PARP-7 seems to be involved in T-cell function, and its 
induction by TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin) contributes to tumor 
promotion (Ma et al., 2001). The functions of PARP-14 and PARP-15 are not clear. 
Recently, PARP-10 was found to interact with the proto-oncoprotein c-Myc in affinity 
column purification experiments in our lab. Interaction of c-Myc and PARP-10 was 
also shown in GST-pulldown experiments in vitro and in overexpressed systems in 
vivo. 
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Although PARP proteins are related through their PARP homology domain, they do 
not resemble each other outside of that region and hint at their discrete functions. In 
some cases, the unique domains specify interaction with a protein acceptor of ADP-
ribosylation, such as the ankyrin domain in tankyrase, which binds the acceptor TRF1 
(Smith et al., 1998), or the C-terminal domain of VPARP, which binds the acceptor 
MVP (Kickhoefer et al., 1999). The unique domains of PARP family members might 
provide clues to the mechanism of activation. For example, PARP-1 contains a DNA-
binding domain and is activated by DNA damage, whereas VPARP and tankyrase do 
not contain known DNA-binding domains and the mechanism of activation for these 
PARPs is not yet known. It is interesting to note the properties of short PARP-1 
(sPARP-1), a recently isolated alternative form of PARP-1, appears to be the product 
of an alternative initiation event in the PARP-1 gene, starting at amino acid 523 of 
PARP-1, its PARP activity is not stimulated by DNA-strand breaks (Sallmann et al., 
2000). In addition, the fact that these proteins inhabit different subcellular localization, 
for example, inactive PARP-1 in the nucleoplasm, VPARP in cytoplasmic vault 
particles, and tankyrase at telomeres, makes a common function for PARPs unlikely.  
In summary the existence of at least 18 members in the PARP superfamily together 
with their diverse subcellular localizations suggests that these enzymes are associated 
with diverse functions. Although for all 18 members poly(ADP-ribose) polymerase 
activity has not been demonstrated yet, post-translational modification by PAR is most 
likely widespread. It will now be important to define in more detail the cellular 
processes that are regulated by poly(ADP-ribosyl)ation. 
 
1.4 Aims of this study 
The c-Myc oncoprotein regulates different aspects of cell behavior by modulating gene 
expression. It was demonstrated that c-Myc stimulates cell proliferation, inhibits 
differentiation and induces apoptosis. Deregulated expression of c-Myc is a common 
feature of many human malignancies and contributes to the transformation of normal 
to malignant cells. At the molecular level, c-Myc acts as a transcription factor by 
Introduction     
 
22
activating or repressing target genes. It is suggested that c-Myc exerts many function 
by binding to other proteins and several c-Myc-interaction partners play a role in the c-
Myc-dependent regulation of gene expression and cell behavior. Thus, the 
characterization of novel c-Myc-binding proteins could enhance our understanding of 
these processes and in addition lead to novel insight into other functions of c-Myc. 
Therefore a search was undertaken for novel interaction partners of c-Myc. PARP-10 
was found to interact with c-Myc in affinity column purification experiments. In this 
study the first aim was to analyze the biochemical and functional interaction between 
c-Myc and PARP-10. On the one hand in vitro and in vivo binding experiments should 
verify the interaction. On the other hand, the influence of PARP-10 on c-Myc function, 
such as transactivation and transformation, should be investigated. 
In addition, the biological and biochemical properties of PARP-10 should be analyzed. 
PARP-10 belongs to the PARP family, because it contains a region that is 
homologous to the PARP catalytic domain, which in PARP-1 can poly(ADP-ribosyl)ate 
many protein substrates, including histones, and several other nuclear proteins. PARP 
enzymes are involved in the regulation of many cellular processes such as DNA 
repair, genomic stability, cell cycle progression, cell death and gene transcription. 
Because, until now, PARP-10 has not been characterized, the second aim of this 
study was to analyze PARP-10’s function, e.g. by determining substrates of PARP-10 
and analyzing its cellular localization. 
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2 Results 
2.1 Characterization of PARP-10 
2.1.1 Consensus mapping of PARP-10 
Affinity purification of c-Myc under low stringency conditions revealed several 
associated protein species. From a 150 kDa protein several tryptic peptids were 
microsequenced and with this information a complete cDNA sequence assembled. 
The encoded protein was found to be identical to PARP-10 (Ame et al., 2004). 
Human PARP-10 consists of 1025 amino acids. To obtain further insight into 
potential functions of PARP-10, homology searches were performed to identify 
regions of potential functional relevance, several regions were formed (Figure 2-1). A 
RNA recognition motif (RRM) is localized between amino acids 11 and 85 and exists 
in a variety of RNA-binding proteins, including heterogeneous nuclear 
ribonucleoproteins (hnRNPs), proteins implicated in regulation of alternative splicing, 
protein components of small nuclear ribonucleoproteins (snRNPs) and in single-
stranded DNA-binding proteins (Crowder et al., 1999; Dallaire et al., 2000; Fiset and 
Chabot, 2001). Between amino acid 281 and 399 is a Gly-rich region. Similar regions 
are necessary for alternative splicing activity, for stable RNA binding and for optimal 
RNA annealing activity in hnRNP A1 (Ginisty et al., 2001). A Glu-rich region (aa 588-
697) overlapps with a PARP domain (aa 632-1013), which shows homology to 
catalytic domains of PARP enzymes. There is a potential nuclear export signal (NES) 
between amino acids 598 and 607 which is localized in the Glu-rich domain. NES are 
important for the nuclear export of proteins (Fornerod et al., 1997; Fukuda et al., 
1997; Ossareh-Nazari et al., 1997; Kudo et al., 1998). The PARP domain contains 
two ubiquitin-interacting motifs (UIM, aa 650-667 and aa 673-690). UIM is present in 
numerous proteins involved in a variety of cellular processes including endocytosis, 
protein trafficking, and signal transduction (Polo et al., 2003). A ubiquitin-binding 
motif is required for intramolecular monoubiquitylation, which is a regulatory signal, 
like phosphorylation, that can alter the activity, location or structure of a protein. 
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Figure 2-1. Consensus mapping of PARP-10. The protein sequence of full length PARP-10 is 
displayed here. RRM (in red), a Gly-rich region (in green), a Glu-rich region (in bluegreen), NES (in 
yellow), and UIM (in bluegreen) are shown. The PARP domain is shaded in gray.  
 
2.1.2 Subcellular distribution of PARP-10  
The subcellular localization of other PARP family member varies: PARP-1 and 
PARP–2 were observed in the nucleus, while tankyrases show multiple subcellular 
localizations. To study the localization of PARP-10, immunofluorescence 
experiments with PARP-10 specific antibodies were performed.  
First, PARP-10 was transiently transfected in U2OS cells, overexpressed PARP-10 
was stained with the monoclonal PARP-10 antibody 5H11 (Figure 2-2). As 
mentioned above, PARP-10 contains a potential Leu-rich NES motif, which was 
described as a CRM1 (chromosomal region maintenance protein 1)-dependent 
export signal. Such NES elements have been formed exists in many proteins, whose 
Results  25 
 
nuclear export can be inhibited with leptomycin B (LMB), a streptomyces metabolite. 
The toxin LMB inhibits CRM1-mediated export by interacting directly with CRM1 and 
 
Figure 2-2. PARP-10 shuttles between the cytoplasmic and the nuclear compartments. (A) HA-
PARP-10 was expressed transiently in U2OS cells and stained by indirect immunofluorescence using 
mAb (monoclonal antibody) 5H11. (B) Endogenous PARP-10 was analyzed in the absence and 
presence of LMB in T47D cells. Controls identify samples that were not incubated with the primary 
antibody (mAb 5H11) but only with the secondary antibody. The exposure times were identical for the 
stainings with and without primary antibody. Prior to fixation and staining the cells were treated with or 
without 50 nM leptomycin B (LMB) as indicated for 2 hours. 
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disrupting the trimeric Ran-GTP-CRM1-NES export complex. To understand whether 
PARP-10 shuttles between the nucleus and the cytoplasm by a CRM1-dependent 
mechanism, the influence of LMB on the subcellular localization of PARP-10 was 
analyzed by immunofluorescence experiments. Subsequently, the endogenous 
localization of PARP-10 was analyzed in T47D cells, which contain the highest 
amount of PARP-10 in comparison to cells of all lines investigated (data not shown). 
The results show that HA-PARP-10, transiently expressed in U2OS cells, and 
stained with 5H11, was predominantly localized in the cytoplasm, no staining was 
observed in untransfected cells (Figure 2-2 A, upper panel). DNA staining was 
performed to identify nuclear or cytoplasmic localization, phase contrast pictures 
show the position of the cells. These stainings were done in order to detect the 
differences of PARP-10’s localization according to the special treatment with LMB. 
After the treatment with LMB (Figure 2-2 A, lower panel), overexpressed PARP-10 
accumulated efficiently in the nuclear compartment, indicating that PARP-10 shuttles 
between the cytoplasm and the nucleus. This suggests that nuclear export of PARP-
10 is a CRM1-dependent mechanism.  
T47D cells were used to analyze the localization of endogenous PARP-10 (Figure 2-
2 B). The results show that in untreated cells (Figure 2-2 B, upper panel) PARP-10  
was localized both to the cytoplasmic and the nuclear compartments, whereas after 
LMB treatment (Figure 2-2 B, lower panel) PARP-10 was preferentially localized in 
the nucleus. No staining was visible in the absence of the primary antibodies. This 
confirms that the export of endogenous PARP-10 is probably CRM1-dependent. 
A sequence alignment of the Leu-rich nuclear export sequences (NES) of several 
proteins known to be exported in a CRM1-dependent mechanism and the potential 
NES from PARP-10 was performed and presented in table 1.  
The comparison indicates that PARP-10 contains a perfect NES signal (Table 1). To 
characterize the function of the potential NES in PARP-10, three leucine residues 
were replaced with alanines to create PARP-10-∆NES. The plasmid expressing this 
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mutated protein was then transiently transfected into U2OS cells and the subcellular 
localization of the resulting protein was analyzed (Figure 2-3).  
 
Protein name sequence 
P53 NESs: Human 340    M F R E L N E A L E L K    351 
 Mouse 337    M F R E L N E A L E L K    348 
 Rabbit 338    M F R E L N E A L E L K    349 
 Cow 333    M F R E L N D A L E L K    344 
 Xenopus 313    M I K K L N D A L E L Q    324 
 Zebrafish 316    I L K K L N D S L E L S    327 
P51      M L L K I K E S L E L M     
P63      M L L K I K E S L E L M     
P73  367    I L M K L K E S L E L M     
MDM2  197      L S F D E S L A L C    206 
LIMK1 NES1 231    I R N V P L D E I D L L    242 
 NES2 243   I Q E T S R L L Q L T L E    255 
HIV REV   71    L Q L P P L E R L T L D    82 
a-actin NES1 170    A L P H A I M R L D L A    181 
 NES2 211    D I K E K L C Y V A L D    222 
Zyxin  319    L T M K E V E E L E L L    330 
Dsk-1  308    S L E G A V S E I S L R D   320 
MAPKK  33 N L V D L Q K K L E E L E L D E Q Q 50 
PKI-a  33 N S N E L A L K L A G L D I N K T E 50 
C-ABL  1086 A I N K L E S N L R E L Q I C P A T 1103 
Rev  70 P V P L Q L P P L E R L T L D C N E 87 
Ran-BP1  176 H A E K V A E K L E A L S V K E E T 193 
FMRP  425  K E V D Q L R L E R L Q I D E Q L 441 
IKB-a  261 P S T R I Q Q Q L G Q L T L E N L Q 278 
TFIIIA  326 S K A D P L P V L E N L T L K S S N 343 
Hdm2  185 S D S I S L S F D E S L A L C V I R 202 
PARP-10 human 598     L L A T L E G L D L     607 
     NES CONSENSUS           L X (1-3)  L X (2-3)  L   X   L 
Table 1. NES sequence alignment of PARP-10 and other NES containing proteins. 
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Figure 2-3. Nuclear export of PARP-10 is dependent on the NES motif. (A) The consensus 
sequence of Leu-rich nuclear export sequences (NES) is given (top). The potential NES of PARP-10 is 
indicated (middle). The mutations introduced into the sequence are indicated in red (bottem). (B) HA-
PARP-10-∆NES was expressed transiently in U2OS cells and stained by indirect immunofluorescence 
using mAb 5H11. DNA was identified by Hoechst stain. A phase contrast picture of the labeled cells is 
shown. Arrows identify two transfected cells. 
Immunofluorescence experiments show that the resulting protein, HA-PARP-10-
∆NES, was predominantly localized to the nucleus. These findings suggest that 
PARP-10 shuttles between the cytoplasmic and the nuclear compartments and that 
the shuttling is dependent on the NES motif. 
 
2.1.3 PARP-10 inhibits cell proliferation 
One aim of this study was to analyze the functions of PARP-10 and the effect of this 
protein on cell proliferation. To analyze the function of PARP-10, a cell line with 
stably integrated, inducible TAP (Tandem Affinity Purification) tagged PARP-10 was 
generated by the Flp-In-Trex 293 cell line system. This allows after doxycylin 
treatment a high induction of PARP-10 expression and a quick purification of PARP-
10 protein complexes by TAP tag. In this study, cell lines were generated which 
express wild type of PARP-10 (c-Tap-PARP-10), PARP mutant of PARP-10 (c-Tap-
PARP-10-GW), NES mutant of PARP-10 (c-Tap-PARP-10-∆NES) and dopple 
mutant of PARP-10 (c-Tap-PARP-10-GW
 
-∆NES). 
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First, the expression of the PARP-10 proteins in all cell lines was analyzed by 
western blotting (Figure 2-4). The PARP-10 expression was induced by doxycyclin 
and cells were lysed at different time points as indicated. The expression of c-TAP-
PARP-10 clone 5, c-TAP-PARP-10 clone 7, c-TAP-PARP-10-GW clone 4 and c-
TAP-PARP-10-GW clone 7 were shown. Nucleolin was also immunoblotted as a 
loading control. The expression of PARP-10 in other cell lines (c-TAP-PARP-10-
 ∆NES and c-TAP-PARP-10-GW- ∆NES) were analyzed as well. In all cell lines 
PARP-10 and its mutants were expressed within 2-4 hours after induction (Figure 2-4 
and data not shown).  
 
Figure 2-4. Protein expression of in TAP-tagged PARP-10-inducible cell lines. 293 cells with 
stably integrated c-TAP-tagged PARP-10 (c-TAP-PARP-10 clone 5, c-TAP-PARP-10 clone 7, c-TAP-
PARP-10-GW (glycine 888 in the active center mutated to tryptophane) clone 4, and c-TAP-PARP-10-
GW clone 7) were treated with doxycyclin and lysed at the time points as indicated in F-buffer, 
separated by SDS-PAGE and immunoblotted with PARP-10 mAb 5H11. Nucleolin was immunoblotted 
as loading control. 
The effect of PARP-10 on cell proliferation was analyzed with MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) measurement. MTT (yellow) is 
metabolized (reduced) by mitochondrial succinic dehydrogenase of proliferating cells 
to formazan (purple), which can be quantified by spectrophotometry. MTT assays 
were performed with the inducible cell lines. The cells were seaded in a 96 well plate  
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Figure 2-5. PARP-10-dependent growth inhibition of cells expressing TAP-tagged PARP-10. 
MTT assays were performed in c-TAP-PARP-10-expressing cell lines described in materials and 
methods. Extinction was measured at the time points as indicated. The expression of PARP-10 or 
PARP-10 mutant was indicated with doxycyclin at 0 hour (non-induced: red, induced: green). (A) c-
TAP-PARP-10 clone 5, (B) c-TAP-PARP-10 clone 7, (C) c-TAP-PARP-10-GW clone 4, (D) c-TAP-
PARP-10-GW clone 6, (E) c-TAP clone 1. Stars indicate significant differences at that time point 
according to student-T test, n=6. The mean values and standard deviations of two experiments. DOX: 
doxycyclin. -: without induction. +: with induction. 
and, at different time points the cells were treated with MTT which is reduced by a 
proliferating cell to formazan. Because this causes a change in color dependent on 
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the amount of the proliferating cells, the number of cells can be determined. By 
measuring at several different time points, a growth curve can be established. The 
difference between the growth curve of induced and uninduced cells of the same cell 
line indicates the effect of induced protein on the proliferation of this cell line. 
The MTT assays showed that upon induction of PARP-10, cells grew significantly 
slower (Figure 2-5 A and B green lines) than the cells without induction (Figure 2-5 A 
and B red lines). When PARP-10-GW was expressed no growth inhibition was 
observed indicating that the PARP-10-dependent growth inhibition is dependent on 
the PARP domain (Figure 2-5 C and D). This suggests that the PARP-10 inhibits cell 
proliferation and that this is dependent on the PARP activity. Upon the induction of c-
TAP-PARP-10
 
-∆NES, cells grew slower than the cells without induction (growth 
curves similar to that from c-TAP-PARP-10, data not shown). No difference was 
observed between the growth curves of induced and uninduced cells which express 
c-TAP-PARP-10-GW-
 ∆NES (data not shown). 
 
2.1.4 PARP-10 does not have an effect on colony formation 
The effect of an overexpressed protein on the growth of immortalised or transformed 
cells can be determined with colony formation experiments. Plasmids encoding 
PARP-10, PARP-10-∆NES, PARP-10-GW or PARP-10-GW-∆NES were transfected 
in U2OS cells (Figure 2-6); in order to select the transfected cells, a neomycin 
resistant marker was cotransfected. An empty vector was used as a negative control. 
After 21 days of selection in the presence of G418, the number of colonies were 
counted. The colony numbers from the plates which transfected with PARP-10, 
PARP-10-∆NES and PARP-10-GW are less than that from the vector, while the 
colony number from the plates which transfected with of PARP-10-GW-∆NES is 
more than that from the vector.  
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Figure 2-6. The overexpression of PARP-10 has no effect on colony formation. Colony formation 
assays were performed in U2OS cells as described in materials and methods. The mean values and 
standard deviations of two experiments (four plates each experiment) are shown.  
 
2.1.5 PARP-10 possesses PARP activity 
2.1.5.1 Glycine 888 is the catalytic center of PARP-10 
Consensus mapping shows that the C-terminal half of PARP-10 has limited 
homology to the catalytic domain of PARP-1. Previous experiments showed that the 
C-terminus of PARP-10 contains PARP activity (data not shown). PARP activity was 
also detected with full length PARP-10. The relatedness of human PARP-10 with the 
PARP domain of ck (chicken)-PARP-1 was analyzed by fold recognition algorithms. 
The human PARP-10 sequence is compatible with the architecture of a PARP 
domain and the three-dimensional structure of the catalytic domain of PARP-10 was 
modeled according to this alignment using the coordinates of ck-PARP-1 as 
template. Several amino acids in the active center are conserved, e.g. glycine at 
position 888. To determine the importance of this amino acid for the PARP activity of 
PARP-10, a single point mutant was generated and tested for PARP activity. Briefly, 
glycine was mutated to tryptophane in an eukaryotic expression vector with an HA-
tag (generated by E. Poreba), this plasmid was then transiently transfected in 293 
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cells and the resulting protein was immunoprecipitated with HA antibodies and tested 
for PARP activity.  
 
Figure 2-7. G888 is the catalytic center of PARP-10. HA-PARP-10 and HA-PARP-10-G888W were 
overexpressed in HEK 293 cells. 1 x 107 cells were lysed in F-buffer and immunoprecipitated using 
mAb against the HA-tag, analyzed by western blot and PARP assays were performed with the 
immunoprecipitated proteins. 
To determine the function of G888 for PARP-10, the wild type PARP-10 was also 
used in this assay as a positive control. In control western blot both wild type PARP-
10 (HA-PARP-10) and mutated PARP-10 (HA-PARP-10-G888W) showed 
comparable levels of protein expression (Figure 2-7, upper panel). In the 
autoradiography (Figure 2-7, lower panel), wild type PARP-10 (HA-PARP-10) 
revealed autopoly(ADP-ribosyl)ation activity while HA-PARP-10-G888W showed 
strongly reduced activity, supporting the prediction from the structure model that 
G888 within the catalytic center of PARP-10. 
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2.1.5.2 PARP-10 derived from PARP-10-inducible cell line shows PARP activity 
To analyze the PARP activity of the respective proteins in PARP-10 stable cell lines, 
cells were treated with doxycyclin for 6 hours, the induced PARP-10 was then 
immunoprecipitated with the specific antibody 5H11 and tested for PARP activity. 
 
Figure 2-8. PARP activity of PARP-10 derived from PARP-10-inducible cell lines. 3 x 107 cells of a 
293 cell line with inducible c-TAP-tagged PARP-10: c-TAP-PARP-10 clone 5, c-TAP-PARP-10-GW 
clone 4, c-TAP-PARP-10-∆NES clone 6 and c-TAP-PARP-10-GW-∆NES clone 6 were lysed in F-
buffer, immunoprecipitated with PARP-10 specific antibody 5H11, washed 3 times with F-buffer and 
seperated by SDS-PAGE or tested for PARP assay. Subsequently, proteins were immunoblotted with 
monoclonal PARP-10 antibody 5H11 or detected by autoradiography. As control for 
immunoprecipitation the same amount of lysate was used without any antibody. IP: 
immunoprecipitation. 
The immunoprecipitation (IP)-western blot indicated that all four cell lines showed 
similar levels of protein expression. The autoradiography indicates that PARP-10 
proteins from the wild type (c-TAP-PARP-10 clone 5) and the single mutant of NES 
consensus (c-TAP-PARP-10-∆NES clone 6) cell lines showed autopoly(ADP-
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ribosyl)ation activity, while the protein from the single PARP mutant cell line (c-TAP-
PARP-10-GW clone 4) and the double mutant cell line (c-TAP-PARP-10-GW-∆NES 
clone 6) showed a strong reduction of autopoly(ADP-ribosyl)ation activity as 
expected. This confirmed that G888 is within the catalytic center of PARP-10, and 
showed that the PARP-10 protein with a single mutation of NES has PARP activity 
as well. 
 
2.1.5.3 Substrates of PARP-10 
So far only autopoly(ADP-ribosyl)ation of PARP-10, to understand the function of this 
novel c-Myc interaction partner, it is important to search for substrates of this novel 
poly(ADP-ribosyl)ation enzyme. In vivo, the most abundant substrate of PARP-1 is 
PARP-1 itself. Auto-poly(ADP-ribosyl)ation represents a major regulatory mechanism 
for PARP-1’s function, that results in the down-regulation of the enzymatic activity 
(Okayama and Hayaishi, 1978; Levy-Wilson, 1981; Mennella et al., 1982; Poirier et 
al., 1982b; Tanuma et al., 1983; Adamietz and Rudolph, 1984; Adolph and Song, 
1985b; Adolph and Song, 1985a; Tanuma et al., 1985; Krupitza and Cerutti, 1989a; 
Krupitza and Cerutti, 1989b; Scovassi et al., 1993; Ullrich and Grune, 2001). In 
addition to PARP-1, histones are also considered to be major acceptors of poly(ADP-
ribose). Recently, several transcription factors, DNA replication factors, and signaling 
molecules including NF-κB, AP-2, Oct-1, YY1, B-MYB, DNA-dependent protein 
kinase, p53, topoisomerase I, lamin B, and B23 have been demonstrated to become 
poly(ADP-ribosyl)ated by PARP-1 in vitro (Nie et al., 1998; Miyamoto et al., 1999; 
Anderson et al., 2000; Cervellera and Sala, 2000; Hassa and Hottiger, 2002). To 
identify additional substrates for PARP-10 besides itself, c-Myc, histone H1, core 
histones and nucleosomes were tested to be poly(ADP-ribosyl)ated by GST-PARP-
10(588-1021) or GST-PARP-10(700-1021), which contain the catalytic domain of 
PARP-10. GST was used as a negative control. 
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Figure 2-9. Core histones can be poly(ADP-ribosyl)ated by PARP-10. GST-PARP-10(588-1021) or 
GST was incubated with 32P-NAD+ in the presence or absence of a mixture of the four core histones or 
individual core histones as indicated. Coomassie blue (CB) stained gels and the corresponding 
autoradiography (32P) are displayed.  
A mixture of the four core histones and individual core histones were incubated with 
GST-PARP-10(588-1021) or with GST alone. The autoradiography indicates that all 
four core histones can be poly(ADP-ribosyl)ated by GST-PARP-10(588-1021), while 
no signal was observed in the presence of GST alone (Figure 2-9, lower panel). In 
addition, this data shows that histone H2A was the best substrate of PARP-10 as 
compared to the other core histones. The existence of all core histones was shown 
(Figure 2-9, upper panel) in the coomassie blue staining. 
To map the poly(ADP-ribosyl)ation site of H2A used by PARP-10, four deletion 
mutants of H2A were generated and fused to a GST tag. These proteins were then 
expressed in E. coli, purified, and incubated with GST-PARP-10(700-1021) in a 
PARP assay. 
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Figure 2-10. Mapping of the poly(ADPribosyl)ation site in H2A used by PARP-10. (A) Sequence of 
full length H2A and four deletion mutants of H2A that are generated. Lower panel shows the relative 
position of these four deletion mutants in H2A. The glutamic acid residues are market in red. (B) Full 
length H2A, GST-H2A∆1, -∆2, -∆3, and -∆4 were incubated in the presence or absence of GST-PARP-
10(700-1021) and 32P-NAD+. Coomassie blue (CB) stained gel and the corresponding autoradiography 
(32P) are displayed. Molecular weight of the protein marker is indicated. 
Full length of H2A and all four deletion mutants of GST fusion proteins of H2A were 
tested whether they can be poly(ADP-ribosyl)ated by PARP-10, thereby the full 
length H2A served as a positive control. The autoradiography showed that the full 
length H2A and the GST-H2A∆1 were poly(ADP-ribosyl)ated by PARP-10, whereas 
the other three deletion mutants were not. All proteins were expressed (Figure 2-10 
B, upper panel). This suggests that the domain in H2A which is poly(ADP-
ribosyl)ated by PARP-10 lies within the N-terminus (aa 1-61) of H2A. Generally, the 
poly(ADP-ribosyl)ation takes place on glutamic acid residues (Riquelme et al., 1979; 
Ogata et al., 1980a; Ogata et al., 1980b), since there are two glutamic acid residues 
in H2A-∆1 (market in red in Figure 2-10 A, upper panel), one or both of them might 
be the poly(ADP-ribosyl)ation site for PARP-10. 
Histone H1 has been shown previously to be poly(ADP-ribosyl)ated by PARP-1 
(Ogata et al., 1980b). But in vitro histone H1 cannot be poly(ADP-ribosyl)ated by 
PARP-10 (Figure 2-11 A). The poly(ADP-ribosyl)ation of H1 was tested with GST-
PARP-10(588-1021) and GST-PARP-10(700-1021). In the autoradiography no band 
was observed at the H1 protein level. Nucleosomes (gift of J. Vervoorts) (Figure 2-11 
B) and MBP-c-Myc (Figure 2-11 C) were also tested for poly(ADP-ribosyl)ation. 
Briefly, nucleosomes were tested with GST-PARP-10(700-1021) and MBP-c-Myc 
was tested with GST-PARP-10(588-1021), both were not substrates of PARP-10 
(Figure 2-11 B and C). 
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Figure 2-11. Histone H1, nucleosomes, and c-Myc are not substrates of PARP-10. (A) GST-
PARP-10(588-1021), GST-PARP-10(700-1021), or GST was incubated with 32P-NAD+ in the presence 
or absence of core histones or H1 as indicated. The upper panels show Coomassie blue (CB) stained 
gels and the lower panels the corresponding autoradiography (32P). Arrowheads indicate the positions 
of the core histones and H1. (B) GST-PARP-10(700-1021) or GST was incubated with 32P-NAD+ in the 
presence or absence of core histones or nucleosomes as indicated. The upper panels show 
Coomassie blue (CB) stained gels and the lower panels the corresponding autoradiographies (32P). 
Arrowheads indicate the positions of histones and nucleosomes. (C) GST-PARP-10(588-1021) or GST 
was incubated with 32P-NAD+ in the presence or absence of MBP or MBP-c-Myc as indicated. The 
upper panels show coomassie blue (CB) stained gels and the lower panels the corresponding 
autoradiography (32P). Arrowheads indicate the positions of MBP and MBP-c-Myc. Molecular weight of 
the protein marker is indicated. 
 
2.2 Biochemical and functional interaction of PARP-10 and c-Myc  
PARP-10 was identified as a novel c-Myc-interacting protein in affinity purification 
experiments with the c-Myc specific mAb 6A10, which recognizes an N-terminal 
epitope in c-Myc (Sommer et al., 1998). To verify the binding of PARP-10 to c-Myc, 
in vivo and in vitro interaction experiments were performed.  
 
2.2.1 In vivo interaction of PARP-10 and c-Myc 
To confirm the interaction of c-Myc and PARP-10 in affinity purification experiments, 
in vivo interaction assays of PARP-10 and c-Myc were performed by endogenous co-
immunoprecipitation. T47D and U2OS cell lines were used in these experiments 
since they contain the highest amount of PARP-10 among all cell lines investigated 
(data not shown). Endogenous c-Myc was immunoprecipitated with c-Myc specific 
monoclonal or polyclonal antibodies and tested for the presence of PARP-10 in an 
IP-western blot.  
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Figure 2-12. Endogenous PARP-10 interacts with endogenous c-Myc in vivo. 5 x 107 T47D cells 
were lysed in F-buffer, immunoprecipitated with the antibody α-c-Myc N262, washed 3 times with F-
buffer and seperated by SDS-PAGE, and then immunoblotted with monoclonal antibody 5H11 specific 
for PARP-10. As control immunoprecipitation the α-cytochrome C antibody was used. 6 x 107 U2OS 
cells were lysed in F-buffer. For the immunoprecipitation the monoclonal α-c-Myc antibodies 4H3 were 
used, as negative control served the α-HA antibodies 3F10 or without antibodies. Cyt. C: Cytochrome 
C. IP: immunoprecipitation. 
Endogenous interaction of PARP-10 and c-Myc is shown in Figure 2-12. 
Endogenous c-Myc was immunoprecipitated with polyclonal antibody N262 from the 
lysates of T47D cells or with mAb 4H3 U2OS cells. With PARP-10 specific antibodies 
5H11 in the IP-western blot, PARP-10 was observed in both cell lines, and in the 
negative control lanes no signal was detected. This confirmed that PARP-10 and c-
Myc interact in vivo. 
 
2.2.2 PARP-10 interacts with c-Myc in a stable cell line 
In a stable cell line the interaction of PARP-10 and c-Myc were analyzed. After 
induction of PARP-10 with doxycyclin, c-Myc was immunoprecipitated with specific 
antibodies and TAP tagged PARP-10 was tested in IP-western blot. 
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Figure 2-13. PARP-10 interacts with c-Myc in a cell line stably integrated inducible PARP-10. 2 x 
107 c-TAP-tagged PARP-10 (clone 5) cells (with or without induction) were lysed in F-buffer and 
immunoprecipitated with the pAb (polyclonal antibody) α-c-Myc N262, washed 3 times with F-buffer, 
seperated by SDS-PAGE, and immunoblotted with monoclonal antibody 5H11 specific for PARP-10 . 
As control immunprecipitation the α-cytochrome C antibody was used. Doxycyclin induction was 
performed for 6 hours. Cyt. C: Cytochrome C. IP: immunoprecipitation. 
The Figure 2-13 show that upon the treatment of doxycyclin, TAP tagged PARP-10 
proteins were expressed. In addition, interaction of TAP tagged PARP-10 and c-Myc 
was determined in this experiment. Endogenous c-Myc was immunoprecipitated with 
pAb N262 and TAP tagged PARP-10 was observed in the immuno blot. In this 
experiments TAP tagged PARP-10 wild type clone 5 was used. The interaction was 
also shown in other TAP tagged PARP-10 clones and mutant cell lines (data not 
shown). This suggests that TAP tagged PARP-10 interacts with c-Myc in this stable 
cell line. 
 
2.2.3 Colocalization of PARP-10 and c-Myc in the nucleus  
c-Myc is a nuclear protein (Luscher, 2001). This study indicates that PARP-10 
shuttles between cytoplasm and nucleus (Figure 2-2 and 2-3). To further evaluate 
the interaction of PARP-10 and c-Myc, colocalization of two protein was analyzed by 
indirect immunofluorescence experiments. Since cells are three-dimensional, the 
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overlapping of diverse proteins in different layers can also cause a false conclusion 
of colocalization. A more precise conclusion of proteins colocalization can therefore 
be performed with confocal microscopic analysis. Since PARP-10 was preferencially 
localized in the cytoplasm, LMB was used to block the nuclear export of PARP-10 
and to increase the amount of nuclear PARP-10. Unfortunately, endogenous c-Myc 
cannot be detected with the available antibodies. c-Myc was therefore transiently 
overexpressed in T47D cells, because in these cells endogenous PARP-10 can be 
observed. 
 
Figure 2-14. Endogenous PARP-10 colocalizes with c-Myc. Flag-c-Myc was transiently expressed 
in T47D cells and stained by indirect immunofluorescence using pAb N262. Endogenous PARP-10 
was stained with 5H11. Confocal microscopic analysis is used here. The cells were treated without 
(upper panel) or with LMB (middle panel). The lower panel displays the enlargment of one transfected 
cell seen in the middle panel. Prior to fixation and staining the cells were treated with or without 50 nM 
leptomycin B (LMB) as indicated for 2 hours. 
Flag-c-Myc was stained by indirect immunofluorescence using polyclonal antibody 
N262. Endogenous PARP-10 was stained with monoclonal antibody 5H11. Both 
were visualized by confocal microscopy, c-Myc is shown in green and PARP-10 in 
red. In the absence of LMB, PARP-10 localized predominantly in the cytoplasm, little 
colocalization of PARP-10 and c-Myc (yellow in merge) was observed. After LMB 
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treatment, PARP-10 accumulated exclusively in the nucleus. A strong partial 
colocalization of PARP-10 and c-Myc in the nucleus was detected (lower panel). This 
suggests that when PARP-10 is forced to remain in the nucleus, c-Myc and PARP-10 
colocalize. 
 
2.2.4 c-Myc interacts with PARP-10 in the nucleus 
The bimolecular fluorescence complementation (BiFC) approach is based on the 
formation of a fluorescence complex, when two fragments of a fluorescence protein 
are brought together by an interaction between proteins fused to the fragments 
(Grinberg et al., 2004). The interaction of c-Myc and PARP-10 should be observed 
with this method and the location of the interacting proteins can be determined as 
well. Complementary fragments of yellow fluorescence protein YFP (YN and YC) 
were fused to PARP-10 and c-Myc. If c-Myc interacts directly with PARP-10, a 
complex should form and YFP fluorescence should be observed in the fluorescence 
microscope. Plasmids encoding all combinations of the fusion proteins were 
transfected into HEK 293 cells including BIFC-YN-PARP-10 alone, BIFC-YC-c-Myc 
alone, and BIFC-YN-PARP-10 together with BIFC-YC-c-Myc. The cells were 
monitored by fluorescence microscopy.  
 
Figure 2-15. Visualization of PARP-10 and c-Myc interaction in living cells. (A) BIFC-YN-PARP-10 
and BIFC-YC-c-Myc were co-expressed transiently in HEK 293 cells. YFP indicated the fluorescence 
resulting from the interaction of c-Myc and PARP-10. DNA was identified by Hoechst stain. A phase 
contrast picture of the labeled cells is shown. (B) Control western blot for expression of BIFC-YN-
PARP-10 and BIFC-YC-c-Myc. Molecular weight of the protein marker is indicated.  
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BIFC-YN-PARP-10 and BIFC-YC-c-Myc were cotransfected in 293 cells. The 
existence of YFP fluorescence (Figure 2-15 A) suggested that PARP-10 interacts 
with c-Myc. The resulting YFP fluorescence was observed exclusively in the nucleus, 
indicating that the interaction of PARP-10 and c-Myc happens in the nucleus of living 
cells. This supports the observation that PARP-10 and c-Myc interact in the nucleus 
shown before by confocal microscopic analysis (Figure 2-14). A control western blot 
shows the expression of the proteins (Figure 2-15 B). No YFP fluorescence was 
observed by transfection with BIFC-YN-PARP-10 alone or BIFC-YC-c-Myc alone. 
 
2.2.5 c-Myc binds to the C-terminus of PARP-10  
It was shown that PARP-10 binds to at least two domains within c-Myc, one in the N-
terminal 156 amino acids requiring Myc box II (MBII), the other in the C-terminal 176 
amino acids (Yu et al., 2005). To analyze the interaction domain of c-Myc in PARP-
10, GST-pulldown experiments were performed. Briefly, deletion portions of PARP-
10 were fused to a GST tag. These fusion proteins were expressed in E. coli and 
purified and used together with in vitro transcribed/translated, 35S-methionine-labeled 
c-Myc in GST-pulldown experiments. Three deletion mutants of PARP-10 were 
generated and fused to GST tags. GST-PARP-10(1–907) contains the first 907 
amino acids, GST-PARP-10(588–1021) the amino acids between 588 and 1021 and 
GST-PARP-10(700–1021) consist of the amino acids 700 to 1021. GST protein was 
used as a negative control. 
The GST-pulldown experiment indicated specific binding of c-Myc to all three PARP-
10 mutants, whereas no binding was observed to GST (Figure 2-16, lower panel). All 
GST fusion proteins of PARP-10 and GST were expressed (Figure 2-16, upper 
panel). This suggested that c-Myc binds to a region encompassing aa 700–907 
within the C-terminal half of PARP-10. 
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Figure 2-16. Mapping of the c-Myc interaction domain of PARP-10. In vitro transcribed/translated 
35S-methionine-labeled c-Myc was incubated with GST, GST-PARP-10(1-907), GST-PARP-10(588-
1021) or GST-PARP-10(700-1021). The proteins were analyzed by SDS-PAGE. A Coomassie blue 
stained gel is displayed with GST and the different GST-PARP-10 fusion proteins indicated by 
arrowheads (upper panel). c-Myc was identified by autoradiography (lower panel). 10% of the input is 
shown in the input lane. Molecular weight of the protein marker is indicated. 
 
2.2.6 PARP-10 represses the c-Myc-dependent transactivation 
To understand the influence of PARP-10 on the functions of c-Myc, the effect of 
PARP-10 on c-Myc-dependent transactivation was investigated. This was performed 
with transient transfection and reporter gene experiments. For this increasing amount 
of PARP-10 and c-Myc were coexpressed with M4-tk-luc in HEK 293 cells. The 
reporter construct M4-tk-luc encodes for the luciferase and contains four c-Myc 
binding elements in front of a minimal tk-promoter. Since PARP-10 and c-Myc can 
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form a stable complex in the BIFC system (Figure 2-15), transactivation assays were 
performed in this system.  
 
Figure 2-17. PARP-10 represses c-Myc-dependent transactivation. (A) BIFC-YN-PARP-10 was 
expressed transiently in HEK 293 cells and stained by indirect immunofluorescence using mAb 5H11. 
DNA was identified by Hoechst stain. A phase contrast picture of the cells is shown. (B) Cotransfection 
of BIFC-YN-PARP-10 and BIFC-YC-c-Myc in HEK 293 cells. Transfected cells were stained by indirect 
immunofluorescence using mAb 5H11 and pAb N262. DNA was identified by Hoechst stain. A phase 
contrast picture of the labeled cells is shown. (C) HEK 293 cells were transfected with M4-tk-luc (c-Myc 
reporter plasmid) and increasing amounts of BIFC-YN-PARP-10 with or without 1 µg BIFC-YC-c-Myc. 
The relative luciferase activity was measured. The activity without BIFC-YN-PARP-10 and BIFC-YC-c-
Myc was set to one. RLA: relative luciferase activity. The mean values and standard deviations of three 
experiments. 
Subcellular localization of BIFC-YN-PARP-10 was analyzed by indirect 
immunofluorescence. Cotransfection of BIFC-YC-c-Myc resulted in an exclusively 
nuclear localization of PARP-10 while PARP-10 transfected alone localized in 
cytoplasm as expected (Figure 2-17). Without cotransfection of PARP-10, the 
relative luciferase activity of c-Myc activated is about 3 fold. Cotransfection of PARP-
10 resulted in a reduction of luciferace activity. Thus the reporter gene assay 
suggested that PARP-10 represses the c-Myc-specific gene activation. This suggests 
that PARP-10 is a novel potential cofactor of c-Myc. Transactivation assays done 
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with BIFC-YN-PARP-10-GW which contain the PARP mutant showed similar effect 
as BIFC-YN-PARP-10.  
 
2.2.7 PARP-10 inhibits c-Myc/Ha-Ras- and E1A/Ha-Ras-dependent 
transformation  
It is well known that c-Myc can transform primary rat embryo fibroblasts together with 
Ha-Ras, an activated form of Ras, in cotransformation assay. Since PARP-10 can 
interact with c-Myc, it should be investigated, whether PARP-10 can influence the c-
Myc-dependent transformation. Ha-Ras ist constitutively active due to a point 
mutation of amino acid 12 that changes glycine to valin (G12V), this mutation inhibits 
the GTPas activity of Ras and therefore Ha-Ras is constitutively active. 
The principle behind the focus formation assays is that primary and immortalized 
cells grow in a monolayer and stop proliferating when they are confluent and contact 
each other. This phenomenon is referred to as contact inhibition. In contrast, 
transformed cells are not contact inhibited. They show unregulated growth properties 
and form in a monolayer of non-transformed, contact-inhibited cells a thick focus that 
is visible by the naked eye. The cotransformation experiments described here were 
performed in co-operation with Dr. Cerni, University of Vienna. 
To identify the influence of PARP-10 on transformation, focus formations assays of 
primary REFs with c-Myc/Ha-Ras were performed in the absence or presence of 
PARP-10. PARP-10 proteins with ∆NES and/or GW mutations were also used for 
this assay to understand the functions of these domains for PARP-10 (Figure 2-18 A 
and B). Primary REFs were stably transfected with plasmids expressing c-Myc, Ha-
Ras, PARP-10 and it mutants. The formed foci were stained and the number of the 
foci were counted. Transformation by c-Myc/Ha-Ras was inhibited by co-expressing 
PARP-10, PARP-10(1–907), or PARP-10(G888W) in a dose-dependent manner. In 
contrast, mutants that are predominantly localized in the nucleus and are probably 
unable to shuttle (PARP-10∆NES and PARP-10∆NES-G888W) did not inhibit  
Results  49 
 
 
Results  50 
 
Figure 2-18. PARP-10 inhibits transformation by c-Myc/Ha-Ras and E1A/Ha-Ras. (A) Giemsa 
staining of the cell culture dishes 12 to 14 days after which primary rat embryo fibroblasts were 
cotransfected with plasmids expressing c-Myc and Ha-Ras in the presence or absence of plasmids 
encoding the indicated PARP-10 proteins. Foci stain dark. Large foci are frequently lost during staining 
and are represented by unstained areas on the dish. (B) Summary of the effects of PARP-10 and 
PARP-10 mutants on c-Myc/Ha-Ras transformation of REFs. The number of colonies of control 
transformations was set to 100% (corresponding to 60-80 foci per plate for c-Myc/Ha-Ras). For control, 
vector only or the plasmid encoding Ha-Ras alone were used. Between 0 and 4 small foci per plate 
were observed (not shown). For each combination of plasmids 6 dishes were analyzed per experiment. 
The mean values and standard deviations of 6 (with PARP-10, 1-907, and G888W) and 2 (with ∆NES 
and ∆NES-G888W) experiments are shown. (C) Effects of PARP-10 and PARP-10 mutants on 
adenoviral E1A/Ha-Ras transformation of REFs. The number of colonies of control transformations 
was set to 100% (corresponding to 150-200 foci per plate for E1A/Ha-Ras). For each combination of 
plasmids 6 dishes were analyzed per experiment. The mean values and standard deviations of four 
(PARP-10 and 1-907) and two (with ∆NES-G888W) experiments are shown. The cotransformation 
experiments were performed in co-operation with Dr. Cerni, University of Vienna. 
transformation. All mutants were expressed equally (data not shown). The influence 
of PARP-10 on E1A/Ha-Ras-dependent transformation was also tested to know 
whether the inhibition of focus formation is a general effect or specific for c-Myc/Ha-
Ras-mediated transformation. The inhibition of E1A/Ha-Ras-dependent 
transformation was even more pronounced (Figure 2-18 C), again independent of 
PARP activity. Furthermore, PARP-10∆NES-G888W showed little inhibitory activity. 
This indicates that PARP-10 represses the c-Myc/Ha-Ras and E1A/Ha-Ras 
transformation which is not dependent on the PARP activity but on the subcellular 
localization of PARP-10 or its ability to shuttle between the nuclear and 
cytoplasmatic compartments. 
 
Taken together, this study shows that the novel PARP family member, PARP-10, is 
localized to the cytoplasm and the nucleus, PARP-10 contains a functional NES that 
mediates nuclear export which is suggested CRM1-dependent. PARP-10 poly(ADP-
ribosyl)ates itself and core histones, suggesting that it could play a potential role in 
the remodeling of chromatin. PARP-10 shows no growth inhibitory effect on the 
colony formation, but inhibits proliferation in a PARP-10-inducible cell line 
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demonstrating that the influence of PARP-10 on cell proliferation might be complex. 
PARP-10 interacts with the proto-oncoprotein c-Myc in vivo and in vitro, and the 
interaction occurs in the nucleus. Furthermore, c-Myc interacts with the C-terminus of 
PARP-10. PARP-10 can repress the c-Myc-dependent transactivation, indicating that 
PARP-10 is a novel potential cofactor of the proto-oncoprotein c-Myc. Moreover 
PARP-10 inhibits transformation of REFs by c-Myc/Ha-Ras and E1A/Ha-Ras which 
does not depend on the PARP activity but on the subcellular localization of PARP-10 
or shuttling between the nuclear and cytoplasmatic compartments. 
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3 Discussion 
3.1 The biochemical and biological function of PARP-10 
3.1.1 Subcellular localization of PARP-10 
The subcellular localization of overexpressed and endogenous PARP-10 was 
analyzed by immunofluorecent assays (Figure 2-2). The results showed that 
endogenous PARP-10 is localized both in the cytoplasm and nucleus whereas 
overexpressed PARP-10 is predominantly localized in the cytoplasm. The reason for 
the predominantly cytoplasmic localization of overexpressed PARP-10 might be due 
to an overloaded nuclear import system in the cell or the function of NES is 
prominent than the function of NLS. 
The subcellular localization of PARP members are diverse (de Murcia et al., 1994; 
D'Amours et al., 1999; Ame et al., 2004). PARP-1 and PARP-2 are localized in the 
nucleus. PARP-3, PARP-4, PARP-5a, and PARP-5b were observed in the cytoplasm 
and the nucleus. It was suggested that the localization of some of the PARPs is 
regulated during the cell cycle and by interacting partners. PARP-3 has been 
identified as a core component of the centrosome preferentially located at the 
daughter centriole throughout the cell cycle (Augustin et al., 2003). PARP-5a was 
originally described as a telomeric protein whose catalytic activity was proposed to 
regulate telomere function (Smith et al., 1998) but is found at mitotic centrosomes, 
on cytoplasmic fibers of nuclear pore complexes (Smith and de Lange, 1999) and in 
the Golgi complex (Chi and Lodish, 2000). The subcellular localization of PARP-5a 
can be regulated during the cell cycle and by TRF1. In interphase, PARP-5a 
colocalized with TRF1 to telomeres, but in addition was found to reside at nuclear 
pore complexes. At mitosis, concomitant with nuclear envelope breakdown and 
nuclear pore complex disassembly, PARP-5a was found to relocate around the 
pericentriolar matrix of mitotic centrosomes (Smith and de Lange, 1999). PARP-5a is 
also found as a novel target of Mitogen-activated protein kinase (MAPK)signaling at 
the Golgi, where it is tethered to GLUT4 vesicles by binding to insulin-responsive 
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amino peptidase (IRAP) (Chi and Lodish, 2000). Whether the subcellular localization 
of PARP-10 is regulated during the cell cycle- and/or by interacting protein is remain 
to be investigated. 
It was shown that some PARP family members interact with each other, like PARP-1 
with PARP-2 and PARP-3, and PARP-5a with PARP 5b. This type of 
combination/association could involve these complexes in different subcellular 
compartments and with different substrates, which they could not otherwise target as 
individuals. This may highlight a new organizational order for the PARPs that could 
diversify greatly their biological responses, via combinatory interactions. Since 
PARP-10 is localized in cytoplasm and nucleus, it makes possible that PARP-10 
interacts with other PARP protein members. The interation of PARP-10 and other 
family members are not investigated till now, but this should be determined in the 
future, e.g. with the inducible cell line, in which TAP-tagged PARP-10 can be 
expressed, and which enables a fast purification of PARP-10 protein complexes and 
an easy determination of other interaction partners of PARP-10.  
The function of PARP-10 in the cytoplasm is not clear till now. The focus formation 
assay with the mutants that are predominantly localized in the nucleus and are 
probably unable to shuttle (PARP-10DNES and PARP-10DNES-G888W) did not 
inhibit c-Myc/Ha-Ras- and E1A/Ha-Ras-dependent transformation (Figure 2-18): One 
reason might be that PARP-10 stays in the nucleus, and is disabled to bind some 
proteins or factors in the cytoplasm which are important for c-Myc/Ha-Ras- and 
E1A/Ha-Ras-dependent transformation. In this respect the RRM (RNA recognition 
motif) domain in PARP-10 might be important. PARP-10 contains an RRM in the N-
terminus (Figure 2-1). This domain often mediates the specific recognition of RNA 
important for a number of cellular processes, including nucleo-cytoplasmic transport, 
splicing, and protein biosynthesis (Dreyfuss et al., 1996; Nakielny and Dreyfuss, 
1999). The RRM of PARP-10 is highly homologous to the known RRMs of nucleolin, 
hnRNP A1, sex lethal, and PTB (data not shown) (Crowder et al., 1999; Conte et al., 
2000; Dallaire et al., 2000; Fiset and Chabot, 2001; Ginisty et al., 2001). In addition, 
RRMs have also been implicated in the binding of single-stranded DNA relevant for 
telomere maintenance (Crowder et al., 1999; Dallaire et al., 2000; Fiset and Chabot, 
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2001). These homologies indicate a potential role for PARP-10 as an RNA and/or 
ssDNA-binding protein. Thus an interesting possibility is that the RRM motif in PARP-
10 might play a role in the nucleo-cytoplasmic transport of mRNA. PARP-10 contains 
a Gly-rich domain as well. Similar domains are necessary for alternative splicing 
activity, for stable RNA binding and for optimal RNA annealing activity in hnRNP A1 
(Ginisty et al., 2001). From these homologies an important function of the RRM in 
combination with the Gly-rich domain can be postulated that should be investigated 
in the future. 
The functions of other PARP protein members in the cytoplasm is not completely 
unterstood. Another PARP protein member, PARP-4, associates with vault particles 
(Kickhoefer et al., 1999), a cytoplasmic ribonucleoprotein complex that contains two 
other highly conserved proteins, major vault protein (MVP) and telomerase-
associated protein (TEP1) and an untranslated vault RNA (vRNA). It was shown that 
the majority of PARP-4 is cytoplasmic and a fraction of vaults are localized to the 
cytoplasmic face of the nuclear pore complex in isolated nuclei (Chugani et al., 
1993). The function of these unusual particles is unknown, but they may play a role 
in cellular transport and could be associated with multidrug resistance in some cell 
line (Kickhoefer et al., 1999).  
It should be mentioned that in the TAP-tagged Flp-In-Trex 293 cell line the PARP-10-
∆NES or PARP-10-GW-∆NES proteins are localized in the cytoplasm, but not in 
nucleus as expected. This might be because of this specific cell line. This indicates 
that the nuclear-cytoplasmatic shuttling of PARP-10 is complex and should be 
researched in the future. 
 
3.1.2 Transport of PARP-10 
The subcellular localization of PARP-10 was analyzed by immunofluorecent assays 
with overexpressed and endogenous PARP-10 (Figure 2-2). The results showed that 
PARP-10 is localized both in the cytoplasm and nucleus. Upon treatment of the cells 
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with LMB, an inhibitor of Leu-rich NES-mediated nuclear export and CRM1 (Fornerod 
et al., 1997; Fukuda et al., 1997; Ossareh-Nazari et al., 1997; Kudo et al., 1998), 
PARP-10 accumulates in the nucleus. LMB abolishes the association of CRM1 with 
Leu-rich NES motif by binding directly to CRM1, thereby inhibiting nuclear export of 
proteins. Mutation of the NES results in a mutant PARP-10 that resides 
predominantly in the nucleus indicating that this protein is exported from the nucleus 
dependent on the NES. This study indicates that PARP-10 shuttles between the 
cytoplasm and the nucleus and that the nuclear export depends on the NES and 
most likely CRM1.  
The transport of PARP-10 proteins through the nuclear pore should depend on an 
active-transport mechanism, because it has a apparent molecular mass of about 150 
kDa. The nuclear-pore complex is a large structure spanning the nuclear membrane, 
and forms a physical barrier between the cytosol and nucleus. Proteins with a 
molecular mass up to 50 kDa, or up to 9 nm in diameter, can diffuse freely through 
the aqueous channels of the nuclear-pore complex whereas larger molecules are 
transported through the nuclear-pore complex by an active transport. Transport is 
regulated via specific adaptor proteins and Ran, a small GTPase of the Ras family 
that is required for interaction with the nuclear-pore complex (Yoneda et al., 1999). 
Ran exists in a GDP- or GTP-bound form. The GDP-bound form is mainly present in 
the cytosol, whereas the GTP-bound form is present in the nucleus. This gradient is 
the driving force for transport across the nuclear membrane, and is maintained by 
cytosolic Ran-GAP and nuclear RCC1. In the cytosol, Ran-GTP hydrolyses to Ran-
GDP, whereas in the nucleus RCC1 (regulator of chromosome condensation), a 
chromatin-associated Ran-GEF, exchange Ran-GDP into Ran-GTP. Transport 
across the nuclear-pore complex requires adaptor proteins that mediate either import 
or export. These adaptors are called importin or exportin receptors, respectively 
(Komeili and O'Shea, 2001). Importins and exportins recognize specific NLSs and 
NESs, respectively, present in the transported protein. Several NESs are recognized 
by the evolutionary conserved exportin 1 protein, CRM1. A protein bound to CRM1 is 
transported through the nuclear-pore complex via an interaction with Ran-GTP. 
Within the cytosol, the complex containing Ran-GTP is disassembled by Ran-GAP 
and Ran-binding proteins (Komeili and O'Shea, 2001; Kuersten et al., 2001; Dasso, 
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2002). Nuclear import is mediated via importin receptors. In the nucleus, the importin 
receptor binds to Ran-GTP, resulting in the release of the transported protein. The 
dimeric complex of the importin receptor and Ran-GTP is then recycled to the cytosol 
(Kuersten et al., 2001). The presence of an NLS is a prerequisite to transport 
proteins into the nucleus, whereas a NES transport proteins into the cytosol. PARP-
10 proteins accumulate in the nucleus after treatment with LMB. This links CRM1 
function to PARP-10 export. The dramatic effect of LMB suggests an interaction of 
CRM1 with PARP-10. 
PARP-10 does not contain an obvious NLS. Presently it is not clear what mediates 
nuclear uptake of PARP-10. The import system for PARP-10 is not investigated in 
this work. Consensus mapping indicated that PARP-10 contain two UIM (ubiquitin-
interaction motif) regions within the PARP domain. Because UIM motifs have been 
found in proteins that are involved in nuclear import and export (Polo et al., 2003), 
these domains might be relevant for the shuttling for PARP-10. 
The reason for PARP-10’s shuttling between the cytoplasmic and the nuclear 
compartments is not yet clear. Such proteins are involved in regulating many aspects 
of cell physiology, including transport of RNA, aspects of cell cycle control, and 
transcription (Mattaj and Englmeier, 1998; Michael, 2000). The focus formation 
assay with the mutants that are predominantly localized in the nucleus and are 
probably unable to shuttle (PARP-10DNES and PARP-10DNES-G888W) did not 
inhibit c-Myc/Ha-Ras- and E1A/Ha-Ras-dependent transformation (Figure 2-18) 
indicating that the shuttling of PARP-10 might be important for c-Myc/Ha-Ras- and 
E1A/Ha-Ras-dependent transformation. This suggests that the shuttling attribute of 
PARP-10 is involved in at least some aspects of PARP-10’s biological functions. 
 
3.1.3 Biological function of PARP-10 
To understand the function of PARP-10 in cell proliferation, MTT assays were 
performed. MTT (yellow) can be reduced by proliferating cells to formazan (purple), 
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which can be quantified by spectrophotometry. For this purpose, PARP-10-inducible 
cell lines were used. Growth curves were established by measuring at several 
different time points. The MTT assay indicates that upon induction of PARP-10, cells 
grow significantly slower than the cells without induction (Figure 2-5 A and B). When 
a PARP mutant of PARP-10 was expressed no growth inhibition was observed 
(Figure 2-5 C and D). This result indicates that the growth inhibition by PARP-10 is 
dependent on the PARP activity. In addition, the effect of PARP-10 on the growth of 
immortalised or transformed cells was determined with colony formation 
experiments. PARP-10 wild type, PARP-10-∆NES, PARP-10-GW or PARP-10-GW-
∆NES were transfected in U2OS cells (Figure 2-6), after selection for stable 
transfections with G418 for three weeks, the number of colonies were counted. 
Weak effects were observed in PARP-10 wild type and three mutants compared with 
the vector. These results indicate that PARP-10 is not a general growth inhibitor.  
The results from MTT assay and colony formation assay seem to be contradictory. 
However, in the colony formation assay, the number of the colonies was counted, 
and this cannot reflect the growth rate of the colony; in the MTT assay, a growth 
curve was established, and this indicates the growth rate of the cells. This indicates 
that PARP-10 is not a general growth inhibitor, but PARP-10 modulate cell 
proliferation. In addition the MTT assay indicates that the growth inhibition effect in 
these cell lines is PARP-dependent. The slower growth could be caused by different 
means: e.g. depletion of energy or cell cycle inhibition. This is explained below. 
First, it is possible, that a depletion of energy caused by increased PARP activity in 
the used cell lines results in a slow growth. NAD+ is an essential cofactor in energy 
metabolism. The synthesis of ATP and the balance of the redox potential directly 
depend on NAD+ levels in cells (Voet, 1995). NAD+ is also the precursor or 
immediate substrate for the synthesis of PAR. The hydrolysis of the N-glycosidic 
bond found between the nicotinamide and the ribose moieties of NAD+ produces a 
free energy of -34.3 kJ/mol (-8.2 kcal/mol) (Zatman et al., 1953), which makes this a 
high-energy bond. The energy liberated by the hydrolysis of this bond is used by 
PARPs to catalyse the synthesis of PAR. The level of poly(ADP-ribosyl)ation in cells 
seems to be the most important factor for the maintenance of NAD+ levels. Indeed, it 
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has been demonstrated that the catabolism of NAD+ in mammalian cells occurs 
mainly via poly(ADP-ribosyl)ation reactions (Wielckens et al., 1983; Carson et al., 
1986; Schraufstatter et al., 1986). PARP uses substantial amounts of NAD+ and can 
lower considerably the levels of ATP in cells (Eguchi et al., 1997; Leist et al., 1997). 
The observation that the cell lines expressing PARP-10-GW protein do not grow 
slower might support this explanation. Together, one reason for slower growth speed 
of PARP-10 induced cell line might be the reduction of NAD+, ATP, and the resulting 
reduction of energy level in these cells. 
Second, the inhibition of cell proliferation might be caused by cell cycle inhibition. 
Again this could be divided in three different hypotheses, namely c-Myc-dependent, 
other PARPs-dependent and independent of these two mechanisms. The inhibition 
of proliferation in these cell lines might be c-Myc-dependent, because of the 
interaction of PARP-10 and c-Myc. c-Myc has been demonstrated to play an 
important regulatory role in cell proliferation, and some c-Myc target genes promote 
cell cycle progression. Indeed c-Myc can transcriptionally activate genes including 
cyclin D2, CDK 4 and CDC 25. The expression of these and other target genes leads 
among other effects to the degradation of p27kip1 and the activation of CDK 2 by 
removing inhibitory phosphosylation sites. An important consequence of these 
effects is the activation of Cylin E/CDK 2. This kinase complex, together with D-type 
kinase complexes, and these inactivates the pocket proteins (RB). Together these 
events result in overcoming the G1/S transition and inactivation of the G1/S 
checkpoint (or restriction point) (Sherr and Roberts, 1999; Ekholm and Reed, 2000; 
Adams, 2001). It was shown that PARP-10 can repress the c-Myc-dependent 
transactivation (Figure 2-17). This hints that PARP-10 might as well repress the c-
Myc-dependent transactivation of the cyclin D2-promoter and/or some other 
promoters, which could cause the reduction of cell proliferation. To prove this 
evidence, c-Myc target genes which are involved in cell cycle progression should be 
tested for the expression difference in the PARP-10-inducible cell lines. The 
inhibition of cell proliferation could also be dependent on other PARPs, which are 
involved in cell cycle progression (described below). Third, the inhibition of cell 
proliferation by PARP-10 could be caused by the interaction with some unknown 
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factor or factors that are not involved in cell cycle regulation. All there aspects should 
be clarified in future experiments. 
There is evidence that PARPs are involved in cell cycle progression. It has been 
shown recently in syncytial Drosophila embryos that in response to DNA lesions 
centrosomes are inactivated. This results in a block to chromosome segregation and 
prevents proliferation of cells that are genomically instabil (Takada et al., 2003). It 
was suggested that several PARPs associate with centrosomes, telomeres, 
centromeres and microtubules. A number of recently identified partners of PARP-1 
and PARP-2 such as CENP-A, CENP-B, Bub 3 and Aurora B are clearly involved in 
the organization of pericentric chromatin and in the mechanics of cell division (Ame 
et al., 2004). In response to DNA damage during mitosis, poly(ADP-ribosyl)ation of 
Aurora B by PARP-1 and/or PARP-2 regulates negatively its kinase activity derived  
at Ser10 of histone H3 and inhibits metaphase progression (Ame et al., 2004). 
PARP-1 is a chromosomal passenger that associates with kinetochores of cells 
prepared for nuclear division and later on localizes to the bundled filaments forming 
the central spindle and finally the contractile ring. The localizations of PARP-1 during 
the metaphase–anaphase transition as well as the anaphase–telophase transition 
varies suggesting that PARP-1 may play a possible role in maintaining genome 
stability and segregation fidelity during cell division by controling the cell cycle 
progression at various stages in response to DNA damage (Ame et al., 2004). 
PARP-2 localizes to centromeres during prometaphase and interacts with CENP-A, 
CENP-B and Bub3 (Saxena et al., 2002a; Saxena et al., 2002b). The disruption of 
the mouse parp-2 gene leads to sensitization to ionizing radiation and 
monoalkylating agents associated with preferential centromeric breaks, a prominent 
G2/M accumulation, acquisition of 8N DNA content and a significant level of 
anaphase bridges. In addition, VPARP was also suggested to be involved in cell 
cycle progression, since it is associated with the mitotic spindel during mitosis 
(Kickhoefer et al., 1999). A novel role for PARP-1 as a factor that integrates cyclin-
dependent kinase signaling with gene transcription was suggested (Santilli et al., 
2001). Recently it was reported that PARP-1 binds to and enhances B-MYB 
transactivating potential (Cervellera and Sala, 2000). B-MYB is a potentially 
oncogenic transcription factor involved in mammalian cell proliferation, survival and 
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differentiation (Nomura et al., 1988; Sala and Watson, 1999). B-MYB gene 
expression is growth-regulated and the B-MYB protein is phosphorylated during S 
phase by cyclin A or E/CDK 2 kinase, resulting in augmented transactivating 
potential (Reiss et al., 1991; Robinson et al., 1996). PARP-1 functions also as a B-
MYB cofactor by promoting cyclin/CDK 2-dependent B-MYB phosphorylation (Santilli 
et al., 2001). These suggesten that PARPs are involved in cell cycle progression. 
Whether PARP-10 colocalizes or interacts with these PARP members is not 
investigated in this thesis. 
Thus, PARPs may target specific signal network proteins via poly(ADP-ribose) and 
regulate their functions. Poly(ADP-ribosyl)ation plays a central role in genome 
stability and is involved in DNA replication and repair, gene expression, cell 
differentiation, and transformation. To analyze the functions of PARP-10 the 
identification of the new interaction partners of PARP-10 is required. 
 
3.1.4 Poly(ADP-ribosyl)ation by PARP-10  
The analysis of PARP-10 indicated that its potential PARP domain only has a very 
limited homology at the amino acid level to the PARP domain of PARP-1. However, 
three-dimensional modeling revealed that the C-terminal region of PARP-10 folded 
into a domain similar to the PARP domain of ck-PARP-1 (Yu et al., 2005). Therefore 
it was important to investigate the poly(ADP-ribosyl)ation activity of PARP-10. 
PARP-10 can poly(ADP-ribosyl)ate not only itself (Figure 2-7 and 2-8) but also core 
histones (Figure 2-9). This indicates that PARP-10 might be involved in chromatin 
remodeling.  
Chromatin remodeling modulation by PARP-1 and PARG has become a focus of 
research in recent years. It was shown that purified PARP-1 could ADP-ribosylate 
chromatin proteins (e.g., H1 and core histones) which results in decondensation of 
chromatin and destabilization of nucleosomes (Poirier et al., 1982a). Polyanionic 
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PAR can attach to proteins or act as a free polymer, as a core histone binding matrix. 
PAR can act as a histone acceptor and further destabilize the nucleosomes (Mathis 
and Althaus, 1987; Realini and Althaus, 1992). Poly(ADP-ribosyl)ated decondensed 
chromatin can be refolded by the addition of PARG (de Murcia et al., 1986). Indeed, 
the antagonistic action of PARP and PARG in chromatin regulation results in 
reversible histone exchange reactions. This conclusion is also supported by the work 
of Althaus and associates (Eki, 1994), who have shown that PAR turnover renders 
DNA accessible to nuclease when core histones are incubated with DNA; upon re-
hydrolysis of the polymer by PARG, the DNA becomes resistant to nuclease activity. 
The modulation of chromatin architecture by poly(ADP-ribosyl)ation reactions is very 
important, because chromatin structure regulates several nuclear processes, 
including DNA transcription, replication and repair. The well established role of 
histones as PAR acceptors in vivo (Wielckens et al., 1983; Thraves et al., 1985; de 
Murcia et al., 1988) indicates that the physiological functions of PARP are likely to be 
mediated, at least in part, through the reorganization of chromatin structure in living 
cells. Several other chromatin associated proteins are poly(ADP-ribosyl)ated in vivo. 
Indeed, protamines and high-mobility group (HMG) proteins 1, 2, 14 and 17 have 
been shown to be modified by PARP under various conditions in living cells (Wong et 
al., 1977; Tanuma et al., 1983; Johnson and Ralhan, 1986). A correlation has been 
established between the level of poly(ADP-ribosyl)ation of chromatin proteins, 
especially HMG proteins, and the level of transcription of genes (Tanuma et al., 
1985; Singh and Dixon, 1990; Tsai et al., 1992; Ding et al., 1994; Aoki et al., 1995; 
Miyamoto et al., 1999). PARP-10 can ADP-ribosylate core histones, which hints that 
PARP-10 can remodel chromatin as well. Whether PARP-10 can poly(ADP-
ribosyl)ate other chromatin proteins was not systhematically investigated. However, 
since the substrates of PARP-10’s poly(ADP-ribosyl)ation might be important for 
PARP-10’s biological function, research on substrates of PARP-10’s poly(ADP-
ribosyl)ation should be performed in the future. 
Since the poly(ADP-ribosyl)ation site on core histone H2A was not studied before, 
mapping of the poly(ADP-ribosyl)ation site for PARP-10 was investigated in this 
study. The result shows that the ADP-ribosylation occurs at the N-terminus of histone 
H2A (Figure 2-10). It was shown that rat histone H1 is most frequently poly(ADP-
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ribosyl)ated on residues E2, E14 and possibly E116 (which correspond to E3, E16 
and E115 in the human sequence), as well as on the carboxyl group of the C-
terminal lysine residue, whereas E2 is preferred on histone H2B (corresponding to 
E3 in human H2B) (Riquelme et al., 1979; Ogata et al., 1980a; Ogata et al., 1980b). 
Generally, the poly(ADP-ribosyl)ation takes place on glutamic acid residue, there are 
two glutamic acid residues in H2A-∆1 which covers the N-terminal 1-61 amino acids 
(red marked in Figure 2-10 A, upper panel), one or both of them might be the 
poly(ADP-ribosyl)ation site for PARP-10. This can be investigated by analyzing GST 
fusion proteins with point mutations of the glutamic acid residues (one and both of 
them) of H2A-∆1. It was shown that histones H1, H2A, and H2B are the major 
poly(ADP-ribosyl)ated chromatin proteins (Okayama et al., 1978; Ogata et al., 
1980a). This study shows that PARP-10 cannot ADP-ribosylate histone H1 in vitro. 
(Figure 2-11). Because there might be some factors important for this poly(ADP-
ribosyl)ation, addition experiments should be performed to determine the ability of 
these proteins for poly(ADP-ribosyl)ation. This study shows also that PARP-10 
cannot ADP-ribosylate c-Myc in vitro (Figure 2-11). Some factors might be important 
for this poly(ADP-ribosyl)ation, addition experiments should be investigated. 
We could not detected nucleosomes as substrates for PARP-10 in vitro (Figure 2-
11). Nucleosome might not be a good substrate for in vitro experiments (Nishioka et 
al., 2002) since the nucleosome is high condensed, the accessibility is not good. 
Furthermore this assay was performed with a deletion mutant of PARP-10, additional 
assay should be performed with other enzyme, e.g. TAP-tagged PARP-10. In 
addition, other mechanisms might regulate this modification as well, which was 
explained from the “histone code” hypothesis (Strahl and Allis, 2000; Turner, 2002; 
Iizuka and Smith, 2003; Lachner et al., 2003), other modifications might enhance or 
inhibit the poly(ADP-ribosyl)ation.  
PARP-10’s localization differs from that of PARP-1 and in contrast to PARP-1, 
PARP-10 can poly(ADP-ribosyl)ate all four core histones. This indicates that the 
influence of PARP-10 on chromating remodeling might differ from that of PARP-1. 
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3.2 The functional interaction of PARP-10 with c-Myc 
3.2.1 PARP-10 interacts with c-Myc 
The domain in PARP-10 that binds to c-Myc was identified in vitro with GST-PARP-
10 fusion proteins in GST-pulldown experiments (Figure 2-16). Amino acids 700 to 
907 in the C-terminus of PARP-10 are important for this interaction. A more precise 
identification of the interaction domain is difficult to perform, because shorter GST 
fusion proteins of PARP-10 were unstable (data not shown). The C-terminal c-Myc-
binding region in PARP-10 contains the PARP domain, which is important for the 
poly(ADP-ribosyl)ation of PARP-10. 
In PARP-1 other domains seem to be important for protein-protein interactions. 
PARP-1 contains a leucine-zipper motif N-terminal (Figure 1-3) of the 
automodification domain (Uchida et al., 1993). It has been shown previously that 
protein–protein interactions can be mediated through leucine zippers (Alber, 1993). 
Furthermore several proteins have been shown to interact with PARP-1 through its 
automodification domain. These include the ribosomal proteins L22 and L23a from 
D. melanogaster (Koyama et al., 1999), the transcription factor Yin Yang 1 (YY1) 
(Oei et al., 1997) and Oct-1 (Nie et al., 1998), the human ubiquitin-conjugating 
enzyme hUBC9 (Masson et al., 1997) and histones (Buki et al., 1995). Another 
domain, the BRCT (BRCA1 C-terminus) domain in the automodification domain of 
PARP-1 (Bork et al., 1997) appears to be a fully functional protein-interaction motif, 
since the region of the enzyme containing this motif was shown to interact directly 
with the N-terminal BRCT domain of the XRCC1 (X-ray repair cross-complementing 
1) protein (Masson et al., 1998). A similar BRCT-mediated interaction between the 
BRCT domain of DNA ligase III and the second (C-terminal) BRCT domain of 
XRCC1 has been recently identified (Kubota et al., 1996; Zhang et al., 1998). These 
interactions are responsible for the formation of a DNA-base-excision-repair-specific 
protein complex (Kimchi et al.), and further support the importance of PARP-1 in this 
repair pathway (Masson et al., 1998). PARP-10 might interact with other proteins or 
factors through its RRM region, Gly-rich region and UIM regions as mentioned in 
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3.1.1 and 3.1.2. The investigation of novel interaction partners of PARP-10 is 
essential.  
The interaction between PARP-10 and c-Myc was approved in vivo with co-
immunoprecipitation experiments of endogenous proteins. Endogenous interaction 
can be observed in T47D cells, U2OS cells and in a cell line that stably express 
PARP-10 (Figure 2-12 and 2-13). PARP-10 and c-Myc form a complex in the nucleus 
where c-Myc is localized (Figure 2-15). This gives a hint that PARP-10 could act as a 
cofactor of the transcriptional regulator c-Myc. It also suggests that when PARP-10 is 
in a complex with c-Myc, the prominent function of the NES is repressed. 
The identification of novel interaction partners for PARP-10 was not investigated in 
this study. However, inducible cell lines expressing PARP-10 were successfully 
generated here. These cell lines, in which the induced proteins are TAP tagged will 
allow rapid purification of complexes under native conditions (Puig et al., 2001). In 
order to understand the biological and biochemical functions of PARP-10 in more 
detail, the identification of novel interaction partners will potentially shed light on the 
biological mechanisms PARP-10 is associated with. 
 
3.2.2 PARP-10 represses the c-Myc-dependent transactivation 
To understand the influence of PARP-10 on the functions of c-Myc, the effect of 
PARP-10 on the c-Myc-dependent transactivation was investigated. This was 
performed with transient transfection and reporter gene experiments: PARP-10 and 
c-Myc were coexpressed with M4-tk-luc in 293 cell line. The results indicate that 
cotransfection of PARP-10 yielded a reduction of c-Myc-induced luciferace activity 
(Figure 2-17). The reporter gene assays suggest that PARP-10 represses the c-Myc-
dependent gene activation. This hints that PARP-10 is a novel potential cofactor of c-
Myc, which was also supported by the immunofluorescence experiments (Figure 2-
15). Additional experiments indicate that the plasmid containing the PARP mutant 
shows the same repressive effect on c-Myc-dependent transactivation as the wild 
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type (see 2.2.6). This suggests that in these reporter gene assays the repressive 
effect of PARP-10 on c-Myc-dependent transactivation is PARP domain 
independent. It should be mentioned that PARP-10’s PARP activity might influence 
c-Myc on the chromatin level, which cannot be examined in a reporter gene 
experiment. Poly(ADP-ribysyl)ation of PARP-10 might occur on c-Myc target genes 
or directly affect the function, e.g. the transactivation or repression of c-Myc, which 
was not investigated in this study.  
Because of the functional interactions of PARP-1 and various nonhistone proteins, 
PARP-1 was suggested to act as transcription regulator. PARP-1 modulates 
transcription not only through modification of the chromatin structure, but also by 
direct alteration of the activity of enhancers and promoters (D'Amours et al., 1999; 
Hassa and Hottiger, 2002). The latter occurs in part by functional interactions 
between PARP-1 and various nonhistone proteins, many of which are DNA binding 
transcription factors including NF-κB, B-MYB, Oct-1, nuclear receptors, and the 
HTLV Tax-1 protein (Nie et al., 1998; Miyamoto et al., 1999; Anderson et al., 2000; 
Cervellera and Sala, 2000; Hassa and Hottiger, 2002). PARP-1 may be specifically 
recruited to target promoters by interacting with DNA binding factors through the 
interaction with these sequence specific DNA-binding protein, PARP-1 is targeted to 
defined promoters (Lee et al., 2002). PARP-1 can both activate and repress distinct 
promoters (Butler and Ordahl, 1999; Miyamoto et al., 1999; Soldatenkov et al., 
2002). Furthermore PARP-1 was shown to contact enhancers or promoters directly 
(Plaza et al., 1999; Akiyama et al., 2001; Nirodi et al., 2001; Ha et al., 2002; Zhang et 
al., 2004). It was suggested that PARP-1’s enzymatic activity is required for its 
transcription regulatory functions in some cases (Butler and Ordahl, 1999; Miyamoto 
et al., 1999; Nirodi et al., 2001), whereas in others PARP activity is not required 
(Meisterernst et al., 1997; Anderson et al., 2000; Cervellera and Sala, 2000; Hassa 
and Hottiger, 2002). Also in Drosophila, for example, the expression of PARP-1 
target genes in Drosophila (e.g., the PARP-1 gene itself) is dependent on PARP-e, a 
PARP-1 isoform lacking the catalytic domain (Tulin et al., 2002). Together these 
findings define convincingly that PARP-1 is a bona fide transcriptional cofactor for a 
member of regulatory events controling gene expression. In turn it allows to 
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speculate that PARP-10 might also funcion as cofactor with c-Myc proteins porviding 
the link to sequence and promoter specific effects. 
c-Myc can interact with many proteins and together with these cofactors regulated a 
large number of target genes. c-Myc forms a heterodimer with Max and as a 
Myc/Max heterodimer interacts with E-Box DNA elements. One of the cofactor of c-
Myc is the SWI/SNF complex that contains an ATPase activity involved in 
nucleosome remodeling. In addition c-Myc interacts with TRRAP complexes and 
CBP/p300 (Vervoorts et al., 2003) which possesses HAT activity which are important 
for modulating the acetylation status of core histones and possibly other components 
associated with promoters, including transcription factors and subunits of Pol II 
complex. Finally c-Myc interacts with components of the Pol II complex and may be 
involved in Pol II recruiment. The research on the regulation of PARP-10 on c-Myc-
dependent transactivation or target genes is important for understanding new 
function of c-Myc. 
 
3.2.3 PARP-10 inhibits c-Myc/Ha-Ras- and E1A/Ha-Ras-dependent 
transformation 
To investigate the effect of PARP-10 on c-Myc/Ha-Ras-induced transformation, focus 
formation assays were performed with primary rat embryo fibroblasts (Figure 2-18). 
The data show that PARP-10 can inhibit the c-Myc/Ha-Ras and E1A/Ha-Ras-
dependent transformation of primary REFs’ in a dose-dependent manner. The PARP 
activity does not influence this effect indicating that other domains play a role in 
inhibition of transformation. The mechanism for c-Myc/Ha-Ras and E1A/Ha-Ras 
transformation is not completely clear, however, this indicates that PARP-10 is 
involved in these two pathways.  
In addition, mutated PARP-10 which cannot be exported into cytoplasm cannot 
inhibit these transformations. PARP-10 is a shuttling protein, the reason for PARP-
10’s transport is not yet clear, but such proteins are involved in regulating many 
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aspects of cell physiology, including transport of RNA, aspects of cell cycle control, 
and transcription (Mattaj and Englmeier, 1998; Michael, 2000). The observation, that 
the mutant of PARP-10 which cannot shuttle, lost its inhibiting effect on 
transformation, indicates that the shuttling of PARP-10 or possibly the cytoplasmic 
PARP-10 is important for it’s ability to inhibit the c-Myc/Ha-Ras- and E1A/Ha-Ras-
dependent transformation.  
Furthermore, because reporter gene assays indicate that PARP-10 can repress c-
Myc-dependent transactivation (Figure 2-17), this suggests that the inhibition of 
PARP-10 on c-Myc/Ha-Ras-dependent transformation might be c-Myc-dependent. 
The repression of PARP-10 on c-Myc-dependent transactivation might influence the 
function of c-Myc in gene regulation. To know whether the inhibition of PARP-10 on 
c-Myc/Ha-Ras-dependent transformation depends on the interaction with c-Myc, a 
mutant of PARP-10 should be generated, which cannot interact with c-Myc. The 
establishment of such a mutant could be tested in transactivation and transformation 
assay. This will allow to determine whether the PARP-10 effects the c-Myc function 
are dependent on direct interaction of the two proteins. The transformation assay 
shows that PARP-10 can inhibit the E1A/Ha-Ras-dependent transformation, and 
PARP-10 is involved in this transformation as well. The mechanism of the 
transformation is not investigated in this study. However, because PARP-10 inhibits 
not only the c-Myc/Ha-Ras-dependent transformation, but also the E1A/Ha-Ras-
dependent transformation. It was known that siRNA of rat c-Myc can inhibit the 
E1A/Ha-Ras transformation, this indicate that PARP-10 might also inhibit the 
E1A/Ha-Ras transformation of REFs through inhibition of c-Myc function. Since the 
results from both transformation assays indicate that the NES consensus of PARP-
10 play an important role, the function of cytoplasmic PARP-10 and/or the 
mechanism of PARP-10’s shuttling should be investigated in the future. 
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4 Materials and methods 
4.1 Materials 
4.1.1 Chemicals  
All chemicals were from Amersham, Amicon, AppliChem, Baker, Biomol, BioRad, 
Boehringer, Difco, Du Pont, Eurogentech, Falkon, Fluka, Gibco BRL, ICN, 
Invitrogene, Merck, New England Biolabs, Promega, Riedel-deHaen, Roth, Santa 
Cruz, Seromed, Serva, Sigma and Stratagene verwendet. All materials are from 
company Amershan, Beckman, Biozym, Costar, Eppendorf, Falcon, Fuji, Gilson, 
Greiner, Kodak, Macherey-Nagel, Pharmacia, Qiagen, Sarstedt, Schleicher&Schuell 
and Whatman. 
 
4.1.2 Synthetic oligonucleotides 
The following oligonucleotides were purchased from MWG. 
attB1 G GGG ACA AGT TTG TAC AAA AAA GCA GGC T CC 
ATG TCA GGA CGC GGA AAG CAG 
attB2 G GGG AC CAC TTT GTA CAA GAA AGC TGG GTC 
TTA CTT GTT CTT GCC AGG CTT GTG AC 
attB4 G GGG AC CAC TTT GTA CAA GAA AGC TGG GTC 
CTA CGC GGT CAG GTA CTC GAG G 
attB5 G GGG ACA AGT TTG TAC AAA AAA GCA GGC T CC 
TAC CTG ACC GCG GAA ATT CTG GAG 
attB6 G GGG AC CAC TTT GTA CAA GAA AGC TGG GTC 
CTA GTC ATT CCT TCA CGG CTA GTT GCA G 
attB7 G GGG ACA AGT TTG TAC AAA AAA GCA GGC T CC 
CTG GCG GGC AAC GCG GCT C 
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attB8 G GGG AC CAC TTT GTA CAA GAA AGC TGG GTC 
CTA CGT TTT CTT GGG CAA CAG GAC AG 
attB9 G GGG ACA AGT TTG TAC AAA AAA GCA GGC T CC 
CTC AAC AAG TTA CTC GGG GGT G 
BAMHI-MAARP-TAP CAT GGA TCC AGT GTC TGG GGA GCG GCC CG 
HINDIII-MAARP-TAP CCC AAG CTT ATG GTT GCA ATG GCG GAG GC 
p150nesmut_for CTG CTG GCC ACC GCG GAG GGC GCA GAC GCA 
GAC GGG GAG G 
p150nesmut_rev CCT CCC CGT CTG CGT CTG CGC CCT CCG CGG 
TGG CCA GCA G 
 
4.1.3 Plasmids 
pBS-PARP-10: The EcoRI/SnaBI fragment from pSport(T+B)-PARP-10 was cloned 
into plasmid pBSKS+, which was digested with EcoRI and SmaI. 
pBS-PARP-10-∆NES (M. Yu): pBS-PARP-10 was amplified with oligos 
p150nesmut_for and p150nesmut_rev. 
pEQ176 (J. Lüscher-Firzlaff): The immediate early cytomegalie-virus (CMV)-
promoter constitutively expresses β-Galactosidase in eukaryotic cells. This vector 
has an origin of replication in bacterias (from pBR322) and eukaryotic cells (from 
SV40) and codes for ampicillin resistence. 
pEQ176P2 (J. Lüscher-Firzlaff): β-Galactosidase-cDNA of pEQ176 was removed by 
restriction with PvuII and religation of the rest of the vector.  
pcDNA3Flag-Myc (J. Vervoorts): The BamHI/BglII fragment from BJ-Myc3-wt (B. 
Amati) was cloned into the plasmid pcDNA3-Flag, which was digested with BamHI. 
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pEVRFFO-HA-PARP-10 (J. Lüscher-Firzlaff): The full-length cDNA encodes a 
protein of 1025 amino acids and was cloned into pEV-HA-RF0 (Matthias et al., 1989) 
to obtain pEV-HA-PARP-10. Subsequently, the full-length sequence was published 
by NCBI (AK027370).  
pEVRFFO-HA-PARP-10-GW (E. Poreba): pEVRFFO-HA-PARP-10 was amplified 
with oligos PARP-GW-For and PARP-GW-Rev. 
pEVRFFO-HA-PARP-10-∆NES (M. Yu): The SphI/BssHII fragment from pBS-PARP-
10-DNES was cloned into the plasmid pEVRFFO-HA-PARP-10, which was digested 
with SphI and BssHII. 
pEVRFFO-HA-PARP-10-GW-DNES (M. Yu): The SphI/OliI fragment from pBS-
PARP-10-DNES was cloned into the plasmid pEVRFFO-HA-PARP-10-GW, which 
was digested with SphI and OliI. 
pBIFC-YN: The sequences encoding enhanced yellow fluorescence protein 
containing amino acids 1 to 172 EYFP (1-172) (the N-terminal fragment of YFP 
[YN]), a gift from T. Kerpolla. 
pBIFC-YC: The sequences encoding enhanced yellow fluorescence protein 
containing amino acids EYFP (173-238) (the C-terminal fragment of YFP [YC]), a gift 
from T. Kerpolla. 
pBIFC-YC-c-Myc: The sequences encoding human c-Myc 1-439 (Myc) were fused to 
the N-terminal ends of YC, a gift from T. Kerpolla. 
pBIFC-YN-PARP-10 (M. Yu): The SalI/XbaI fragment from pEVRFO-HA-PARP-10 
was cloned into the plasmid pBIFC-YN, which was digested with SalI and XbaI. 
pcDNA5/FRT/TO/N-TAP (E. Poreba): The NcoI fragment from pBS1761 was treated 
with klenow enzyme and digested with KpnI, ligated with pcDNA5/FRT/TO, which 
was digested with HindIII (klenow) and KpnI. 
Materials and methods  71 
 
pcDNA5/FRT/TO/C-TAP (E. Poreba): The HindIII/KpnI fragment from pBS1479 was 
ligated with pcDNA5/FRT/TO, which was digested with BamHI and NotI. 
pcDNA5/FRT/TO/N-TAP-PARP-10 (E. Poreba): pSport(T+B)-PARP-10 was amplified 
with the oligos HINDIII-MAARP-TAP and BAMHI-MAARP-TAP, then ligated into 
pcDNA5/FRT/TO/N-TAP, which was digested with HindIII and BamHI. 
pcDNA5/FRT/TO/C-TAP-PARP-10 (E. Poreba): The HindIII/BamHI fragment from 
pcDNA5/FRT/TO/N-TAP-PARP-10 was cloned in pcDNA5/FRT/TO/C-TAP, which 
was digested with HindIII and BamHI. 
pcDNA5/FRT/TO/C-TAP-PARP-10-GW (J. Lüscher-Firzlaff): The BssHII/OliI 
fragment from pEVRFO-HA-PARP-10-GW was cloned into pcDNA5/FRT/TO/C-TAP-
PARP-10, which was digested with BssHII and OliI. 
pcDNA5/FRT/TO/C-TAP-PARP-10-∆NES (J. Lüscher-Firzlaff): The SphI/OliI 
fragment from pEVRFO-HA-PARP-10-∆NES was cloned into pcDNA5/FRT/TO/C-
TAP-PARP-10, which was digested with SphI and OliI.. 
pcDNA5/FRT/TO/C-TAP-PARP-10-GW-∆NES (J. Lüscher-Firzlaff): The BssHII/OliI 
fragment from pcDNA5/FRT/TO/C-TAP-PARP-10-∆NES was cloned into 
pcDNA5/FRT/TO/C-TAP-PARP-10, which was digested with BssHII and OliI. 
M4-min-tk-luc (Henriksson et al.): This vector contains four copies of the 
oligonucleotides of the Myc/Max consensus binding element (CMD, Blackwell et al., 
1993) in front of the minimal TK-promoter. 
pGEX-4-T1: Commercial expression vector from Amersham Pharmacia Biotec. The 
gene of interest is under the control of a tac promoter. GST 46 serves as fusion 
protein and affinity tag for purification which can be cleaved by thrombin, the fusion 
protein can be expressed with help of a synthetic lac-promoters induced by IPTG. 
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pGEX4T1-p150-1500 (E. Poreba): pSport-PARP-10 was digested with SmaI and 
ligated with the plasmid pGEX4T1, which was digested with SmaI. 
pGST-PARP-10(588-1021) (E. Poreba): pGEX4T1-p150-1500 was amplified with 
PARP-10-D1-for and PARP-10-D1-Rev. 
pGST-PARP-10(700-1021) (E. Poreba): pGEX4T1-p150-1500 was amplified with 
PARP-10-D2-for and PARP-10-D2-Rev. 
GW-D(221)-H2A∆1 (V. Schumacher): pGEM-H2A was amplified with attB1 and 
attB4. 
pGST-H2A∆1 (V. Schumacher): Gate-way cloning from GW-D(221)-H2Ad1. 
GW-D(221)-H2A∆2 (V. Schumacher): pGEM-H2A was amplified with attB5 and 
attB6. 
pGST-H2A∆2 (V. Schumacher): Gate-way cloning from GW-D(221)-H2Ad2. 
GW-D(221)-H2A∆3 (V. Schumacher): pGEM-H2A was amplified with attB7 and 
attB8. 
pGST-H2A∆3 (V. Schumacher): Gate-way cloning from GW-D(221)-H2Ad3. 
GW-D(221)-H2A∆4 (V. Schumacher): pGEM-H2A was amplified with attB2 and 
attB9. 
pGST-H2A∆4 (V. Schumacher): Gate-way cloning from GW-D(221)-H2Ad4. 
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4.1.4 Antibodies 
α-Flag (M2): Monoclonal IgG1 antibodies from mouse against a synthetic Flag 
peptide (Sigma). 
α-HA (3F10): Monoclonal antibodies from rat, recognizes an epitope between the 
amino acids 98-108 in hemagglutinin of influenza-virus (E. Kremmer). 
α-c-Myc (4H3, 6A10): Monoclonal IgG2a antibodies from rat (E. Kremmer, B. 
Lüscher) recognize N-terminus of human c-Myc. The antibody 4H3 recognizes an 
epitope between the amino acids 55-92, The antibody 6A10 recognizes an epitope 
between the amino acids 7-38.  
α-c-Myc (N262): Affinity purified serum from rabbit recognizes an epitope between 
the amino acids 1-262 of human c-Myc (Santa Cruz). 
α-Nucleolin (MS-3): Monoclonal IgG1 antibodies from mouse, recognizes human 
Nucleolin (Santa Cruz).  
α-PARP-10 (5H11): Monoclonal IgG2a antibodies from rat (E. Kremmer, B. Lüscher), 
recognize human PARP-10.  
 
4.1.5 Bacterial strains 
XL10 gold: TetrD (mcrA)183, D(mcrCB-hsdSMR-mrr)173, endA1, supE44 thi-1, 
recA1, gyrA96, relA1, lac, Hte [F’proAB lacIqZDM15 Tn10 (Tetr) Amy Camr]a 
BL21(DE)pLysS: F-, ompT, hsdsB, (rB-, mB-), dcm, gal_(DE3), pLysS(Cmr) 
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4.1.6 Materials for cell culture 
DMEM (Gibco)     with 4.5 g/l glucose 
MEM (Gibco)      with 4.5 g/l glucose 
RPMI 1640 (Gibco) 
PBS       140 mM NaCl 
2.6 mM KCl 
2 mM Na2HPO4 
1.45 mM KH2PO4 
 
Penicillin/Streptomycin (Seromed)  10.000 units/10.000 µg/ml 
Trypsin/EDTA (Seromed)    0.5/0.02% (w/v) in PBS 
FCS (Gibco)      fetal calf serum 
HS (Gibco)       horse serum 
Pyruvat 
Cell culture plate (Falcon)     diameter 6, 10 cm 
1 ml cryovial (Nalgene) 
 
4.1.7 Eukaryotic cells 
293  adherent cells derived from human embryonic 
kidney transformed with adenovirus 5 DNA (ATCC, 
CRL-1573) 
U2OS     mammalial osteosarcoma cells (ATCC, HTB-96) 
T47D     mammalial carcinoma cells (ATCC, HTB-133) 
Flp-In 293 293 cell line, contains a single integrated FRT site 
and stably expresses the lacZ-Zeocin fusion gene 
from the pFRT/lacZeo plasmid under the control of 
the SV40 early promoter (invitrogen, R750-07) 
c-TAP-PARP-10 clone 5  stable Flp-In 293 cell line, contains PARP-10 which 
is tagged with TAP at the C-terminus, clone 5 
c-TAP-PARP-10 clone 7 stable Flp-In 293 cell line, contains PARP-10 which 
is tagged with TAP at the C-terminus, clone 7 
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c-TAP-PARP-10-GW clone 4  stable Flp-In 293 cell line, contains PARP-10-
G888W mutant which is tagged with TAP at the C-
terminus, clone 4 
c-TAP-PARP-10-GW clone 7 stable Flp-In 293 cell line, contains PARP-10-
G888W mutant which is tagged with TAP at the C-
terminus, clone 7 
 
4.1.8 Culture conditions 
All cell culture medium (except Flp-In 293) contains 1% (w/v) penicillin/streptomycin. 
 
293, U2OS     DMEM with 10% (v/v) FCS 
 
T47D      RPMI 1640 with 10% (v/v) FCS, 1% insulin 
 
4.2 Methods 
4.2.1 DNA methods 
4.2.1.1 Transformation in competent E. coli cells 
agar plate      LB medium 
1.5% (w/v) bacto Agar (Difco) 
100 mg/ml ampicillin 
 
LB medium     1% (w/v) trypton (AppliChem) 
0.5% (w/v) yeast extract (AppliChem) 
1% (w/v) NaCl 
pH 7 
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100 µl of competent cells were mixed with 500 pg-1 ng of plasmid DNA in a snap cap 
and incubated on ice for 20 min. Heat shock was performed at 41.8°C in a water 
bath for 45 seconds; after that bacteria were immediately placed on ice for further 2 
min, then 1 ml LB medium was added and the cells were shaken at 200 rpm on a 
thermal block for 1 hour at 37°C. Finally cells were sedimented at 4.000 g and plated 
on agar plates containing the appropriate antibiotic and incubated at 37°C for 
overnight. 
 
4.2.1.2 Isolation of plasmid DNA from E. coli 
Overnight E. coli cultures were harvested and plasmid DNA was isolated according 
to the manufacturer’s instructions (Qiagen, miniprep and maxiprep-kit). 
Minipreparations were performed for cloning procedures, and maxipreparations were 
used for preparative purposes. Isolated DNA was dissolved in 10 mM Tris/HCl, pH 
8.0 for maxipreperations or in deionized, double-distilled water for sequencing.  
 
4.2.1.3 Quantitative analysis of nucleic acids 
Quantitation of nucleic acids was done with an UV spectrometer, measuring the 
absorption at 260 nm. One unit of absorption corresponds to 50 µg dsDNA. The 
purity of nucleic acids can be determined by measuring the sample at 260 and 280 
nm, respectively. The quotient of A260/A280 should be in the range of 1.8-2.0.  
 
4.2.1.4 Modification of DNA 
Digestion of DNA was performed according to standard instructions. Reaction  
conditions were adapted to the manufacturer’s instructions for the particular 
enzyme(s) used. Incubation times varied between 1 and 4 hours, depending on the 
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cutting properties of the enzyme and the amount of DNA. In order to prevent re-
ligation of vector DNA without insert the terminal 5‘-phosphate was removed by 
treatment with calf intestine phosphatase. Ligation of dsDNA was performed with T4 
DNA ligase. Vector and insert were added at ratios of 10:1, 1:1 and 1:10, 
respectively. For blunt ligation efficiency PEG2000 was added to a final 
concentration of 5%. The ligation reaction was incubated at 16°C for overnight. After 
ligation competent bacteria were transformed with the ligated DNA. All enzymes and 
buffers are from Boehringer Mannheim and New England Biolabs. 
 
4.2.1.5 Molecular cloning by polymerase chain reaction (PCR) 
The DNA fragment was amplified with certain oligonucleotides. The denaturation, 
annealing and elongation time were dependent on DNA (genomic DNA or plasmid 
DNA, GC content of the fragments), primers and the length of the fragments.  
 
4.2.1.6 PCR mutagenesis (site-directed mutagenesis) 
PCR mutagenesis was performed using the QuikChange® mutagenesis kit 
(Stratagene, Heidelberg, Germany) according to the manufacturer's 
recommendation. Primers should be between 25 and 45 bases in length, with a 
melting temperature (Tm) of ≥ 75°C. The following formula is commonly used for 
estimating the Tm of primers: 
Tm = 81.5 + 0.41 x (%GC) – 675 / N (the primer length in bases) - %mismasch 
The desired point mutation or degenerate codon should be close to the middle of the 
primer with ~10–15 bases of template-complementary sequence on both sides. 
Optimum primers have a minimum GC content of 40% and terminate in one or more 
C or G bases at the 3’-end. 
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Briefly, PCR reactions were carried out for single amino acid changes. The PCR 
reaction was composed of double-stranded plasmid DNA as a template, polymerase 
Pfu turbo and a complementary set of sense and antisense primer. Both primers had 
incorporated the desired mutations leading finally to a mutated plasmid.  
Mutagenesis-PCR 
20 ng wild type plasmid 
125 ng primers 
1 µl dNTP mix (25 mM dNTPs) 
5 µl 10x polymerase buffer 
PCR-water add to 49 ml 
1 µl Pfu turbo polymerase (5 U/ml) 
 
PCR program 
98°C  2 min 
18 cycles 96°C 30 sec 
55°C 1 min 
68°C 2 min/kb of plasmid length  
storage 4°C 
 
The methylated, non-mutated parental strand was digested by treatment with the 
restriction enzyme DpnΙ. Subsequently 2 µl of the PCR reaction was transformed into 
competent E. coli XL10 cells. The mutated plasmid sequence was confirmed by DNA 
sequencing. 
 
4.2.1.7 DNA agarose gel electrophoresis and extraction 
DNA-loading buffer     50 mM Tris-HCl, pH 8 
50 mM EDTA 
50% (v/v) glycerin 
0.25% (w/v) BPB 
0.25% (w/v) XC 
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TBE        89 mM Tris-HCl pH 8 
89 mM boric acid 
2 mM EDTA 
loading marker “1kb” (Gibco) 
JETsorb-kit (Genomed) 
 
Analytical and preparative gel electrophoresis of double-stranded DNA fragments 
was performed in 0.8-2% agarose gels supplemented with ethidium bromide (0.1 
mg/ml) as described (Sambrook et al., 1989). DNA fragment sizes were determined 
by using a DNA marker. Bands were visualized using a UV transilluminator at 302 
nm. In preparative electrophoresis the desired DNA fragment was excised with a 
sterile scalpel and extracted with the JETsorb-kit (Genomed). 
 
4.2.2 Methods for cell culture 
4.2.2.1 Cryopreservation 
106–107 cells are trypsinized and collected with medium, centrifuged at 4°C by 1250 
g for 5 minutes, and washed twice with PBS. Cell pellets were then suspended in 1 
ml FCS containing 10% DMSO. The suspension was transferred into cryovials in a 
special box and stored at –80°C for overnight and then in liquid nitrogon at –150°C. 
 
4.2.2.2 Transient transfection 
4.2.2.2.1 CaPO4 method  
The transient transfection of adherent cells was done with the calcium-phosphate-
method (Chen and Okayama, 1988; Bousset et al., 1994). In principle, the co-
precipitated DNA forms in a complex with calcium phosphate and is taken up by 
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endocytosis and is transcribed in the nucleus extrachromosomally. The efficiency of 
this transfection dependend on the cell type and to amount of DNA to approximately 
5-10%. 
 
2 x Hebs buffer      274 mM NaCl 
42 mM HEPES 
9.6 mM KCl 
1.5 mM Na2HPO4 
pH 7.1 
 
HEPES buffer     142 mM NaCl 
10 mM HEPES 
6.7 mM KCl 
pH 7.3 
 
250 mM CaCl2 
 
One day before transfection the cells were split on a plate 1:20, 1.5 x 105 per 6 cm or 
8 x 105 per 10 cm cell culture plate. For 6 cm plates 200 µl 2x Hebs-buffer (500 µl for 
10 cm plate) was mixed briefly with 7 µg (20 µg for 10 cm plate) DNA. 200 µl CaCl2 
was dropwise added to the mixture while shaking vigorously within 10-15 sec, the 
mixture was added then directly dropwise into the culture medium. The plate was 
gently rocked back and forth and from side to side to achieve even distribution of the 
complexes. The plate was then put in the incubator (37°C, 5% CO2). After 4-6 hours 
the medium was replaced by 4 ml (10 ml for 10 cm plate) HEPES buffer at room 
temperature for 10 minutes, and then 4 ml (10 ml for 10 cm plate) fresh medium was 
added. 
For colony formation assays, which were always performed in 10 cm plates, cells in 
one 10 cm plate were splitted into four 10 cm dishes. 24 hours later, medium was 
exchanged with selection medium which contains G418 (final 500 µg/ml). Every 3-4 
days medium was exchanged, until (after about 2-3 weeks) the foci can be observed. 
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4.2.2.2.2 Transfection with the Exgen 500 method 
Transfection was performed according to the protocol supplied. All transfections 
were done with 293 cells in a 24-well plate. Briefly, one day before transfection 1 x 
105 cells was seaded on sterile glass coverslips. On the day of transfection for each 
well 1 µg of DNA was diluted in 100 µl of 150 mM NaCl in a sterile 1.5 ml tube, 
vortexed gently and briefly, and spun down to collect all solution. 3.3 µl Exgen 500 
was then added to the mixture and vortexed immediately for 10 sec to mix. After 10 
minutes incubation at room temperature, 100 µl of the Exgen 500/DNA mixture was 
added to the well. The well plate was gently rocked back and forth and from side to 
side to achieve even distribution of the complexes. 
 
4.2.2.3 Generation of PARP-10 inducible cell lines  
Freshly thawed Flp-In-293 cells were grown in complete medium containing 
blasticidin (15 mg/ml final) and zeocin (100 mg/ml final). The day before transfection 
1.1 x 106 cells were seaded in a 10 cm plate in medium without zeocin. On the day of 
transfection 2 mg pcDNA5/FRT/TO-GO plasmid and 18 mg pOG44 were 
cotransfected using the CaPO4 transfection method. After 2 days the cells were split 
into 4 plates to about 20% confluence. After waiting for 4 - 5 h (or until the cells have 
attached) fresh medium containing hygromycin B (100 mg/ml final) and blasticidin 
(15 mg/ml final) was added. The cells were fed with selection medium every 3 - 4 
days until foci can be identified. 
 
4.2.2.4 Single selection of inducible cell line  
When foci were observed on the plate, single selection of the colonies can be 
performed. After removing the medium, the plate was washed once with PBS. The 
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size with a diameter of about 3-5 mm was chosen for selection. Sterile selection ring 
with silicon fat at one end was put onto the plate and perform a seal area between 
the ring and foci. Trypsin was then added to the ring and incubated at 37°C for 2 
minutes. The cells of one focus were then transferred into a well of a 24-well plate till 
they grew to 70% confluence and moved into a bigger tissue plate. The cells of a 
single selected focus was then checked for inducible protein with doxycyclin 
treatment. 
 
4.2.2.5 Colony formation assay 
The plate was washed once with PBS, dried, and fixed with about 5 ml Giemsa 
solution for 15 min at RT. After washing with water till all background is clear, the 
colony number was counted. 
 
4.2.2.6 Bimolecular fluorescence complementation (BIFC) analysis 
293 cells were transfected with Exgen 500 for 16–18 hours in 24-well plate, 
incubated at 30°C for additional 3 hours to promote fluorophore maturation. 
Afterwords cells were fixed with 4% PFA, permeabilized with 0.2% Triton X-100 in 
PBS for 10 minutes and nucleus was stained with Hoechst for 5 minutes at room 
temperature. After 3 times wash with PBS, slides was mounted with moviol. The cells 
were observed by confocal fluorescence microscopy. YFP fluorescence emission 
was measured at 535 ± 15 nm during excitation at 500 ± 10 nm (Y filters). 
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4.2.3 Biochemical methods 
4.2.3.1 Prepare cell lysates 
F-buffer was used for the analysis of protein from cell line or transient transfected 
cell. 
frackelton buffer (F-buffer)    50 mM HEPES, pH 7.4 
50 mM NaCl 
30 mM Na4P2O7 
100 µM Na3VO4 
10% glycerin 
0.2% (w/v) Triton X-100 
1mM NaF 
1 mM pefa-block 
5 U/ml α-macroglobulin 
2.5 U/ml pepstatin A 
2.5 U/ml leupeptin 
0.15 mM benzamidin 
 
Cells were lysed in F-buffer for 20 min at 4°C. Lysed cells were scrabed and pipetted 
in sterile 1.5 ml tubes. After vortexing for 15 sec and centrifuging at 15.000 upm for 
20 min at 4°C, the supernatant was transferred into a sterile 1.5 ml tube for 
immediate experiments or stored at –80°C. 
 
4.2.3.2 Immunoprecipitation (IP) 
Cell lysate, 20 µl of protein A+G agarose beads (50% slurry) as well as 2 µg antibody 
were added and incubated on a rotation apparatus at 4°C for 1 hour. After removal of 
the supernatant, the precipitates were washed for three times with F-buffer and 
resuspended in 20 µl SDS-sample buffer, stored at –20°C or boiled at 95°C for 5 
minutes and separated by SDS-PAGE.  
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4.2.3.3 Measuring of transactivation 
The regulation of a promoter was investigated by the measurement of the activity of 
a reporter gene product. Promoter fragments were cloned in front of the luciferase 
cDNA. Increased transcription of cDNA correlated with inceased luzciferase activity 
from the cell lysate (Nordeen, 1988). Since the transfection efficiency in one 
transfection varies, 1 µg des β-galactosidase-expression vectors pEQ176 was 
cotransfected per 6 cm plate. The β-galactosidase activity was used to measure the 
transfection efficiency and standardisation of the luciferase activity. 
extraction buffer      25 mM Tris-HCl, pH 7.8 
2 mM EDTA 
10% (v/v) glycerin 
1% (v/v) Triton X-100 
2 mM DTT 
 
Z-buffer       60 mM Na2HPO4 
40 mM NaH2PO4 
10 mM KCl 
1 mM MgSO4 
50 mM β-mercaptoethanol 
 
measuring buffer      25 mM glycylglycine 
15 mM MgSO4 
5 mM ATP, pH 7 
 
1 M Na2CO3 
25 mM luciferin solution 
4 mg/ml ONPG in Z-buffer 
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36 h after transient transfection, cells were washed once with icecold PBS and lysed 
for 10 min with 400 µl extraction buffer. The lysed cells was then scrabted and 
transferred into a sterile 1.5 ml tube and sedimented for 15 min at 4°C and 15.000 
rpm. The supernatant was used for luciferase- and β-galactosidase measurements. 
Luciferase activity was measured with 20 µl lysate in 100 µl measuring buffer in 96-
well plate, and immediately measured in a Biolumator (Victor). The Biolumator injects 
automatically 30 µl luciferin solution and determines the number of photons, which 
are detected within 10 sec. The β-galactosidase activity was measured with 100 µl Z-
buffer, 5 µl lysate and 25 µl ONPG solution in a 96-well plate. The reaction was 
stopped with 250 µl 1 M Na2CO3 as soon as the mixture turned yellow. The β-
galactosidase activity was measured photometrically at 405 nm with Biolumator 
(Victor). Relative luciferase activity was calculated from the quotient of the luciferase 
measurement and the β-galactosidase measurement. The relative luciferase activity 
of the reporter gene activity without co-expression of transcription factor was set as 
one.  
 
4.2.3.4 MTT assay 
3000 TAP tagging cells were seaded on each well of a 96-well plate and incubated 
for overnight at 37°C. 2.5 hours before measurement 25 µl MTT (5 mg/ml in PBS) 
was added to each well and incubated at 37°C. After aspirating the medium, 100 µl 
of 0.04 N HCl/isopropanol was added and the plate was shaked for further 10 
minutes at room temperature. The solution was then diluted with 100 µl H2O and 
mixed well. The MTT activity was measured by spectrophotometry at 570 nm. 
 
4.2.3.5 SDS-PAGE 
SDS-sample buffer     160 mM Tris-HCl, pH 6.8 
20% (v/v) glycerin 
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10% (w/v) SDS 
0.25% (w/v) BPB 
100 mM β-mercaptoethanol 
 
loading buffer      50 mM Tris-Base 
380 mM glycine 
0.1% (w/v) SDS 
 
protein ladder “prestained protein ladder”, about 10-
180 kDa, from MBI-Fermentas 
(#SM0671) 
 
Protein separation under denaturating conditions was done according to the size of 
the protein in a 7.5-20% polyacrylamid (PAA) gel with a 5% stracking in loading 
buffer. The protein was diluted 1:2 in SDS-sample buffer, heated for 5 min at 95°C 
and loaded onto the SDS-PAGE. 
 
4.2.3.6 Coomassie staining 
fixing solution     25% isopropanol 
10% acetic acid 
 
rapid-coomassie-staining-solution  10% acetic acid 
0.006% coomassie brilliant blue G-
250 (Biorad) 
 
amplify from Amersham Biosciences (Code 
Number: NAMP100) 
 
Expressed and purified GST-fusion proteins were separated on SDS-PAA gels, fixed 
for 30 minutes in fixing solution and visualized by rapid-coomassie-staining-solution. 
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Gel was then incubated for 1 hour in staining solution then destained with water and 
dried. 
For autoradiographic visualization of S35 labeled proteins, the gel was incubated with 
amplify for 30 minutes before drying. The film was incubated in dark at –80°C till 
visualization. 
 
4.2.3.7 Western blot 
10 x semi-dry-buffer    250 mM Tris-base 
1.92 M glycine 
pH 8.3-8.8 
 
1 x semi-dry-buffer     10 x semi-dry-buffer 
20% methanol 
mixed freshly 
 
block buffer      PBS 
0.05% (v/v) Tween-20 
5% (w/v) nonfat milk 
 
wash buffer (PBST)    PBS 
0.05% (v/v) Tween-20 
 
Immunoblotting was performed as described (Towbin et al., 1979). Briefly, proteins 
were separated by SDS-PAGE and transferred to nitrocellulose membrane 
containing 1 x semi-dry-buffer. Blots were blocked with 5% nonfat milk for 30 minutes 
at room temperature in PBST and incubated with the primary antibody (3 h at room 
temperature or overnight at 4°C) in PBST. Membranes were washed with PBST and 
incubated with peroxidase-conjugated secondary antibody (1 h at room 
temperature). After three washing steps for 10 minutes, proteins were detected by 
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using the chemiluminescence kit ECL (Amersham, Piscataway, NJ) followed by 
exposure to X-ray films or detected with Las3000. 
 
4.2.3.8 Purification of Glutathion-S-Transferase fusion proteins 
buffer A     50 mM Tris-HCL, pH 8.0 
100 mM NaCl 
0.5% (v/v) Nonidet P-40 
5 mM EDTA 
10 mM DTT 
0.2 mM PMSF 
 
elution buffer     10 mM glutathion in buffer A 
glutathion agarose (Sigma) 
 
BL21 bacteria were transformed with the certain pGEX construct. One colony was 
transferred to a 50 ml LB-amp medium containing 1 mM ZnCl2 and 2% glucose, and 
incubated at 37°C for overnight. Next day the culture was diluted 1:10 and incubated 
till OD reached 0.6 at 37°C. Following the induction with 0.4 mM IPTG for 3-16 
hours, the bacteria were sedimented for 10 minutes at 4°C and 10.000 rpm in the 
JA10 rotor. The pellet was then lysed in buffer A and sonicated for 1-3 minutes. After 
an incubation period of 30 minutes at 4°C, the mixture was sedimented for 20 
Minuten at 4°C and 15.000 rpm in the JA21 rotor. The supernatant was incubated 
with glutathion beads for 1 hour at 4°C on a rotation apparatus. Afterwards the beads 
was washed 3 times with icecold PBS and the protein were eluated with glutathion 
elution buffer through a chromatography column. The concentration of the proteins 
was analyzed with SDS-PAGE and compared to a BSA dilution series, and then 
stained with coomassie blue. 
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4.2.3.9 In vitro translation/transcription 
In vitro translated and [35S]-labeled proteins were prepared according to TNT-system 
(Promega) standard instructions. 1 µl from the reaction mixture was seperated by 
SDS-PAGE. After the gel was incubated with amplify and dried, the signal was 
autoradiographically detected by a film. 
 
4.2.3.10 GST-pulldown 
binding buffer    20 mM Hepes, pH 8 
100 mM NaCl 
0.1 mM EDTA 
0.05% (w/v) Triton X-100 
0.1% aprotinin 
1 mM PMSF 
gluthation agarose 
 
2-5 µg recombinant GST-fusion proteins were bound to 15 µl gluthation-agarose and 
incubated with equivalent amounts of in vitro translated with [35S]-labeled proteins at 
4°C for 90 minutes. The protein complexes were washed for 3 times with binding 
buffer and seperated on a SDS-PAGE. The gel was fixed for 30 minutes and 
incubated with amplify solution for 30 min. After the gel was dried, the signal was 
autoradiographically detected by a film. 
 
4.2.3.11 Immunofluorescence 
4% (w/v) paraformaldehyd in PBS 
0.2% (v/v) Triton X-100 in PBS 
20% horse serum in PBS 
Moviol 4-88 (Hoechst) with isopropylgallat 
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1 mg/ml Hoechst 33258 in PBS 
 
The cells were seeded on sterile coverslips and incubated at 37°C for overnight, for 
overexpressed proteins with a confluence of 40% and for endogenous proteins of 
80%. Following a certain experimental procedure (e.g. transient transfection), the 
cells were washed once with PBS, and fixed with 4% paraformaldehyde in PBS at 
room temperature for 30 minutes. After three times wash with PBS, the cells were 
permeabilized with 0.2% Triton X-100 in PBS for 10 minutes. The coverslips were 
then incubated with the first antibody in a certain dilution in 20% horse serum in PBS, 
which was before usage centrifuged for 30 minutes at 10.000 rpm, to remove the 
insoluble material in horse serum. For 12 mm coverslips 30 µl antibody was loaded 
onto a parafilm, the coverslips were applied onto the parafilm. After an incubation 
period of 30 minutes at 37°C, the coverslips were washed 3 times with PBS, and 
incubated with a secondary antibody for further 30 minutes at 37°C. Afterwards the 
coverslips were washed. To stain the DNA, the coverslips were incubated with 5 
µg/ml Hoechst 33258 in HS/PBS for 5 minutes at room temperature. Following 4 
times wash with PBS, the coverslips were mounted with Moviol onto a slide. The 
slides were dried for overnight at room temperature in dark, and then stored at 4°C. 
The slides were analyzed by fluorescence microscope Olympus IX50 and the 
program AnalySIS. 
 
4.2.3.12 PARP assay 
binding buffer     50 mM Tris-HCl, pH 8  
0.2 mM DTT  
4 mM MgCl2 
 
1 µg bacterially expressed GST-PARP-10 fusion proteins were incubated in binding 
buffer with 1 µCi 32P-NAD+ at 30°C for 30 minutes. Substrates were added in the 
range of 1-2 µg. The reactions were stopped by adding SDS-sample buffer and 
heated at 95°C for 5 minutes. 
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